CA2933921A1 - Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment - Google Patents
Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment Download PDFInfo
- Publication number
- CA2933921A1 CA2933921A1 CA2933921A CA2933921A CA2933921A1 CA 2933921 A1 CA2933921 A1 CA 2933921A1 CA 2933921 A CA2933921 A CA 2933921A CA 2933921 A CA2933921 A CA 2933921A CA 2933921 A1 CA2933921 A1 CA 2933921A1
- Authority
- CA
- Canada
- Prior art keywords
- oral
- dosage form
- bupropion
- trazodone
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010024419 Libido decreased Diseases 0.000 title claims abstract description 138
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 title claims abstract description 138
- 208000017020 hypoactive sexual desire disease Diseases 0.000 title claims abstract description 138
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title claims abstract description 115
- 229960001058 bupropion Drugs 0.000 title claims abstract description 109
- 229960003991 trazodone Drugs 0.000 title claims abstract description 82
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 238000000034 method Methods 0.000 title claims abstract description 79
- 238000011284 combination treatment Methods 0.000 title claims description 13
- 238000011282 treatment Methods 0.000 claims abstract description 50
- 239000003814 drug Substances 0.000 claims description 83
- 239000002552 dosage form Substances 0.000 claims description 72
- 229940079593 drug Drugs 0.000 claims description 64
- 238000013265 extended release Methods 0.000 claims description 33
- 238000013268 sustained release Methods 0.000 claims description 28
- 239000012730 sustained-release form Substances 0.000 claims description 28
- 238000011269 treatment regimen Methods 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 20
- 239000003826 tablet Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000002775 capsule Substances 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 18
- 239000006187 pill Substances 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 16
- 239000000651 prodrug Substances 0.000 claims description 16
- 229940002612 prodrug Drugs 0.000 claims description 16
- 239000007894 caplet Substances 0.000 claims description 14
- 239000012453 solvate Substances 0.000 claims description 14
- 239000007897 gelcap Substances 0.000 claims description 13
- 239000007937 lozenge Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000002459 sustained effect Effects 0.000 claims description 5
- 239000006186 oral dosage form Substances 0.000 claims 32
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 description 95
- 239000000203 mixture Substances 0.000 description 80
- 239000003937 drug carrier Substances 0.000 description 25
- 239000002400 serotonin 2A antagonist Substances 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 18
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 description 18
- 230000001568 sexual effect Effects 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000000018 receptor agonist Substances 0.000 description 17
- 229940044601 receptor agonist Drugs 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- 230000035946 sexual desire Effects 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 12
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 12
- 208000012201 sexual and gender identity disease Diseases 0.000 description 12
- 208000015891 sexual disease Diseases 0.000 description 12
- 230000009429 distress Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- -1 menthol Chemical class 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229960002053 flibanserin Drugs 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229940036329 addyi Drugs 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 5
- 230000036299 sexual function Effects 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000030047 Sexual desire disease Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000037007 arousal Effects 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 208000021663 Female sexual arousal disease Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960000835 tadalafil Drugs 0.000 description 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229940094720 viagra Drugs 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- RNEACARJKXYVND-KQGZCTBQSA-N (2r)-2-[[(5z)-5-[(5-ethylfuran-2-yl)methylidene]-4-oxo-1,3-thiazol-2-yl]amino]-2-(4-fluorophenyl)acetic acid Chemical compound O1C(CC)=CC=C1\C=C/1C(=O)N=C(N[C@@H](C(O)=O)C=2C=CC(F)=CC=2)S\1 RNEACARJKXYVND-KQGZCTBQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 208000024309 orgasm disease Diseases 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to methods of treating women for hypoactive sexual desire disorder (HSDD) with oral daily treatments of low dose and high dose combinations of trazodone and bupropion.
Description
Methods of Treating Women for Hypoactive Sexual Desire Disorder (HSDD) with Bupropion and Trazodone Combination Treatment Cross-Reference to Related Patent Applications This application is related and claims priority to U.S. provisional Application No. 62/351,904, filed on June 17, 2016 and entitled "Methods of Treating Women for Hypoactive Sexual Desire Disorder (HSDD) with Bupropion and Trazadone Combination Treatment", which is incorporated herein by reference in its entirety.
This application is also related to U.S. Patent Application No. 14/045,677, filed on October 3, 2013 and entitled "Treatment Regimens", and U.S. Patent Application No.
14/120,112, filed on August 6, 2013 and entitled "Treatment Regimens", each of which is incorporated herein by reference in its entirety as if fully set forth herein.
Background Hypoactive sexual desire disorder (HSDD) is one of, if not, the most common sexual dysfunction problems presented today to clinicians for diagnosis and treatment. HSDD
affects men and women of all ages. According to myVMC, it is estimated that approximately 20%
of men and 33% of women are affected by low or absent sexual desire. See "Hypoactive Sexual Desire Disorder (HSDD)", reported at http://www.myvinc.com/diseases/hypoactive-sexual-desire-disorder-hsdd/.
HSDD is defined as "a deficiency or absence of sexual fantasies and desire for sexual activity.
The disturbance must cause marked distress or interpersonal difficulty." See Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV-TR), 4th Ed., Text Rev.
Washington, DC: American Psychiatric Association, 2000; and International Classification of Diseases (ICD-10, F52.0).
HSDD can have serious deleterious effects on the overall health of women, their quality of life, and the well-being of their personal relationships. The lack of sexual desire in women may not only cause severe psychological, emotional and/or relationship distress which, in some cases, can be severe and debilitating, it can negatively impact their personal relationships, quality of life, and well-being. HSDD can be a major impediment to life satisfaction and happiness.
[0004] Thus, Clinicians need to understand the implications and address the concerns of their patients.
Unlike other physical disorders, HSDD diagnosis is generally a subjective diagnosis by the health care provider. HSDD diagnosis therefore typically relies upon clinical judgment based on the individual's characteristics, the interpersonal determinants including relationship, the life and home context, and the cultural setting. Women with HSDD typically have a decline in sexual thoughts, a decline in interest in initiating sexual relations, and a decline in being receptive to a partner's initiation.
While HSDD is the most common sexual disorder for women of all ages, to date, it has been difficult to address and the prevalence rates have varied from study to study, as exemplified above and as follows. For example, Segraves and Woodard referenced reports that HSDD
affects between about 5.4% and about 13.6% women. See Segraves R, Woodard T:
Female hypoactive sexual desire disorder: history and current status. J Sex Med, 3(3):408-418 (2006).
West et al. reports that HSDD affects about 8.3% women. See West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM: Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med., 168(13):1441-1449 (2008). The Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking study (the PRESIDE Study) reports that HSDD
affects about 8.9% of women between the ages of 18 to 44, about 12.3% of women between the ages of 45 to 64, and about 7.4% of women who are 65 years in age or older.
Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB: Sexual problems and distress in United States women:
prevalence and correlates. Obstet Gynecol., 112(5):970-978 (2008). Meanwhile, the International Society for Sexual Medicine reports that HSDD affects about 10%
of all women.
See "Hypoactive Sexual Desire Disorder In Women", as reported at http://www.issminfo/who-we-are/public-policy/hypoactive-sexual-desire-disorder-in-women/. See also West SL1, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM: Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women.
This application is also related to U.S. Patent Application No. 14/045,677, filed on October 3, 2013 and entitled "Treatment Regimens", and U.S. Patent Application No.
14/120,112, filed on August 6, 2013 and entitled "Treatment Regimens", each of which is incorporated herein by reference in its entirety as if fully set forth herein.
Background Hypoactive sexual desire disorder (HSDD) is one of, if not, the most common sexual dysfunction problems presented today to clinicians for diagnosis and treatment. HSDD
affects men and women of all ages. According to myVMC, it is estimated that approximately 20%
of men and 33% of women are affected by low or absent sexual desire. See "Hypoactive Sexual Desire Disorder (HSDD)", reported at http://www.myvinc.com/diseases/hypoactive-sexual-desire-disorder-hsdd/.
HSDD is defined as "a deficiency or absence of sexual fantasies and desire for sexual activity.
The disturbance must cause marked distress or interpersonal difficulty." See Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV-TR), 4th Ed., Text Rev.
Washington, DC: American Psychiatric Association, 2000; and International Classification of Diseases (ICD-10, F52.0).
HSDD can have serious deleterious effects on the overall health of women, their quality of life, and the well-being of their personal relationships. The lack of sexual desire in women may not only cause severe psychological, emotional and/or relationship distress which, in some cases, can be severe and debilitating, it can negatively impact their personal relationships, quality of life, and well-being. HSDD can be a major impediment to life satisfaction and happiness.
[0004] Thus, Clinicians need to understand the implications and address the concerns of their patients.
Unlike other physical disorders, HSDD diagnosis is generally a subjective diagnosis by the health care provider. HSDD diagnosis therefore typically relies upon clinical judgment based on the individual's characteristics, the interpersonal determinants including relationship, the life and home context, and the cultural setting. Women with HSDD typically have a decline in sexual thoughts, a decline in interest in initiating sexual relations, and a decline in being receptive to a partner's initiation.
While HSDD is the most common sexual disorder for women of all ages, to date, it has been difficult to address and the prevalence rates have varied from study to study, as exemplified above and as follows. For example, Segraves and Woodard referenced reports that HSDD
affects between about 5.4% and about 13.6% women. See Segraves R, Woodard T:
Female hypoactive sexual desire disorder: history and current status. J Sex Med, 3(3):408-418 (2006).
West et al. reports that HSDD affects about 8.3% women. See West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM: Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med., 168(13):1441-1449 (2008). The Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking study (the PRESIDE Study) reports that HSDD
affects about 8.9% of women between the ages of 18 to 44, about 12.3% of women between the ages of 45 to 64, and about 7.4% of women who are 65 years in age or older.
Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB: Sexual problems and distress in United States women:
prevalence and correlates. Obstet Gynecol., 112(5):970-978 (2008). Meanwhile, the International Society for Sexual Medicine reports that HSDD affects about 10%
of all women.
See "Hypoactive Sexual Desire Disorder In Women", as reported at http://www.issminfo/who-we-are/public-policy/hypoactive-sexual-desire-disorder-in-women/. See also West SL1, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM: Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women.
2 Arch Intern Med., 168(13):1441-9 (July 14, 2008). The variation in prevalence between studies could be due to differences in, for example, the definition of HSDD utilized, data collection methods utilized, age-groups studied, and other selected criteria utilized.
On August 18, 2015, the FDA approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. See http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm458734.htm. To date, Addyi (flibanserin) is the first and only treatment approved by the FDA to treat HSDD.
Unfortunately, Addyi (flibanserin) so far has not apparently enjoyed the same level of success as Viagra or other phosphodiesterase (PDE) inhibitors for the treatment of erectile dysfunction in men. Rather, the sales for Addyi (flibanserin), since launch, have been met with what appears to be considerable disappointment. See, e.g., "Selling 'Female Viagra': Agreement With FDA Forces Sprout Pharmaceuticals To Market Its Low Sexual Desire Pill In New Ways", as reported at http://www.ibtimes.com/selling-female-viagra-agreement-fda-forces-sprout-pharmaceuticals-market-its-low-2147020; "Why Sales of 'Female Viagra' Addyi Have Been So Anticlimactic", as reported at http://time.com/money/4116171/female-viagra-addyi-sales/; "The Female Libido Pill Is No Viagra", as reported at http://www.bloomberg.com/news/articles/2015-11-17/valeant-s-newest-problem-the-female-libido-pill-isn-t-selling; "Female Sex Drug Addyi Not Sprouting Sales for Valeant (VRX)", as reported at http://www.biospace.com/News/female-sex-drug-addyi-not-sprouting-sales-for/399895; and "Pill for Low Libido in Women Goes on Sale on Saturday", as reported at https://www.nlm.nih.gov/medlineplus/news/fullstory 155191.html.
According to the article entitled "Five Studies: Does Flibanserin Provide Real Sexual Benefits for Women?", as reported in Pacific Standard, the Addyi (flibanserin) placebo-controlled trials in HSDD showed only about a 7% improvement over placebo. More specifically, "Nile trial found a trend among outcomes: Women achieved an average of one more "satisfying sexual event" per month on flibanserin. These could include any type of genital stimulation. More than 23 percent of women on flibanserin felt that they were "very much" or "much"
improved, compared with 16.2 percent on placebo." See http://www.psmag.com/health-and-behavior/is-flibanserin-the-real-deal-or-a-pharmaceutical-ploy. In that same Pacific Standard article, it
On August 18, 2015, the FDA approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. See http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm458734.htm. To date, Addyi (flibanserin) is the first and only treatment approved by the FDA to treat HSDD.
Unfortunately, Addyi (flibanserin) so far has not apparently enjoyed the same level of success as Viagra or other phosphodiesterase (PDE) inhibitors for the treatment of erectile dysfunction in men. Rather, the sales for Addyi (flibanserin), since launch, have been met with what appears to be considerable disappointment. See, e.g., "Selling 'Female Viagra': Agreement With FDA Forces Sprout Pharmaceuticals To Market Its Low Sexual Desire Pill In New Ways", as reported at http://www.ibtimes.com/selling-female-viagra-agreement-fda-forces-sprout-pharmaceuticals-market-its-low-2147020; "Why Sales of 'Female Viagra' Addyi Have Been So Anticlimactic", as reported at http://time.com/money/4116171/female-viagra-addyi-sales/; "The Female Libido Pill Is No Viagra", as reported at http://www.bloomberg.com/news/articles/2015-11-17/valeant-s-newest-problem-the-female-libido-pill-isn-t-selling; "Female Sex Drug Addyi Not Sprouting Sales for Valeant (VRX)", as reported at http://www.biospace.com/News/female-sex-drug-addyi-not-sprouting-sales-for/399895; and "Pill for Low Libido in Women Goes on Sale on Saturday", as reported at https://www.nlm.nih.gov/medlineplus/news/fullstory 155191.html.
According to the article entitled "Five Studies: Does Flibanserin Provide Real Sexual Benefits for Women?", as reported in Pacific Standard, the Addyi (flibanserin) placebo-controlled trials in HSDD showed only about a 7% improvement over placebo. More specifically, "Nile trial found a trend among outcomes: Women achieved an average of one more "satisfying sexual event" per month on flibanserin. These could include any type of genital stimulation. More than 23 percent of women on flibanserin felt that they were "very much" or "much"
improved, compared with 16.2 percent on placebo." See http://www.psmag.com/health-and-behavior/is-flibanserin-the-real-deal-or-a-pharmaceutical-ploy. In that same Pacific Standard article, it
3 suggests that `Thesearch suggests that the now-FDA-approved female libido-booster is¨at least in part¨a pharmaceutical ploy." See http://www.psmag.com/health-and-behavior/is-flibanserin-the-real-deal-or-a-pharmaceutical-ploy.
Thus, notwithstanding the overwhelming and growing need to effectively treat women for HSDD, and the approval of Addyi0 (flibanserin) by the FDA, such a treatment still remains elusive and unmet. Consequently, it is apparent that HSDD needs greater attention from healthcare professionals across all clinical disciplines. It is equally apparent that there still is a need for an effective HSDD treatment that can be prescribed to women to treat women for HSDD with therapeutic confidence.
Summary of the Invention The present invention overcomes the drawbacks and disadvantages of the current state of treatments of women for HSDD through the discovery of a novel and effective combination treatment for treating women for HSDD.
Generally speaking, the novel combination treatments of the present invention comprise treating women for HSDD, who are in need of HSDD treatment, with a combination of two drugs, namely, bupropion and trazodone, in accordance with specific treatment regimens. Specifically, the combination treatments of the present invention comprise administering to a woman bupropion either once or twice daily and trazodone once daily, each in amounts effective to treat the woman for HSDD. More specifically, and in accordance with the present invention, the bupropion is administered to a woman in the morning or in the morning and again about 8 hours later in the latter part of the afternoon in two equal dosage amounts and the trazodone is administered to the woman at night, preferably at bedtime, in a single dosage amount. Even more specifically, the bupropion dosage strength that is used in accordance with the present invention to treat women for HSDD, whether administered once daily or twice daily, is 150 mg, and the trazodone dosage strength that is used in accordance with the present invention to treat women for HSDD is 75 mg or 150 mg. Preferably, both the bupropion and trazodone are oral extended release (ER) or sustained release (SR) dosage forms, and the women that are treated for HSDD are premenopausal women.
Thus, notwithstanding the overwhelming and growing need to effectively treat women for HSDD, and the approval of Addyi0 (flibanserin) by the FDA, such a treatment still remains elusive and unmet. Consequently, it is apparent that HSDD needs greater attention from healthcare professionals across all clinical disciplines. It is equally apparent that there still is a need for an effective HSDD treatment that can be prescribed to women to treat women for HSDD with therapeutic confidence.
Summary of the Invention The present invention overcomes the drawbacks and disadvantages of the current state of treatments of women for HSDD through the discovery of a novel and effective combination treatment for treating women for HSDD.
Generally speaking, the novel combination treatments of the present invention comprise treating women for HSDD, who are in need of HSDD treatment, with a combination of two drugs, namely, bupropion and trazodone, in accordance with specific treatment regimens. Specifically, the combination treatments of the present invention comprise administering to a woman bupropion either once or twice daily and trazodone once daily, each in amounts effective to treat the woman for HSDD. More specifically, and in accordance with the present invention, the bupropion is administered to a woman in the morning or in the morning and again about 8 hours later in the latter part of the afternoon in two equal dosage amounts and the trazodone is administered to the woman at night, preferably at bedtime, in a single dosage amount. Even more specifically, the bupropion dosage strength that is used in accordance with the present invention to treat women for HSDD, whether administered once daily or twice daily, is 150 mg, and the trazodone dosage strength that is used in accordance with the present invention to treat women for HSDD is 75 mg or 150 mg. Preferably, both the bupropion and trazodone are oral extended release (ER) or sustained release (SR) dosage forms, and the women that are treated for HSDD are premenopausal women.
4 The moderate dose treatment regimen in accordance with the present invention, i.e., oral bupropion 150 mg twice daily (preferably ER or SR), wherein the first bupropion dosing is administered in the morning and the second bupropion dosing is administered about 8 hours thereafter, and oral trazodone 150 mg once daily (preferably ER or SR), wherein the trazodone is administered once daily at bedtime, is referred to herein as "Moderate Dose Lorexys". The lower dose treatment regimen in accordance with the present invention, i.e., oral bupropion 150 mg once daily (preferably ER or SR), wherein the bupropion is administered once daily in the morning, and oral trazodone 75 mg once daily (preferably ER or SR), wherein the trazodone is administered once daily at night at bedtime, is referred to herein as "Low Dose Lorexys". Thus, the present invention contemplates a daily treatment combination dosage range of between about 75 mg and about 150 mg of trazodone and between about 150 mg and 300 mg of bupropion administered daily. While the trazodone is preferably administered at night and most preferably at bedtime and the bupropion is preferably administered in the morning and/or at night, and more preferably in the morning, the present invention contemplates the administration of both trazodone and bupropion together at any time of the day either in separate dosage forms or in a unitary dosage form that contains both drugs.
Uniquely, the novel combination treatments of the present invention show unexpected superiority over the HSDD treatments for woman available heretofore in efficacy and/or inducing fewer or no side effects. In an HSDD clinical trial for premenopausal women to test safety and efficacy of the Moderate Dose Lorexys and the Low Dose Lorexys, in which standard measures of sexual desire and sexual distress were used, the percentage of women treated with Low Dose Lorexys and Moderate Dose Lorexys who met responder criteria were at about 76%
and about 88%, respectively. In contrast, only 36% and 45%, respectively, of the same women, who were treated with only bupropion SR at the same dosage strengths and in accordance with the same treatment regimens, met responder criteria.
These advantages of the present invention are not just highly statistically significant, p 0.01, they are highly unexpected. The % of women who met the criteria for remission on Low Dose Lorexys and Moderate Dose Lorexys showed similar advantage over bupropion treatment.
In addition, the Low Dose Lorexys and Moderate Dose Lorexys treatments of the present invention are also an advantage over prior treatments in how rapidly patients responded.
Remission typically takes at least 3 months with other treatments, but, with the Low Dose Lorexys and Moderate Dose Lorexys treatments of the present invention, about 58% of the treated women surprisingly met remission criteria within about 4 weeks.
As to side effects, the main side effects of concern to the FDA for drugs in this field have been related to over-sedation, i.e., somnolence, fatigue, dizziness, depression, accidents, and fainting, all of which worsen with alcohol. However, surprisingly and quite unexpected, no sedative-type side effect during the clinical trial was rated as severe for the women treated with the Low Dose Lorexys and Moderate Dose Lorexys of the present invention. Also quite surprising and unexpected, treatment of the women with the Low Dose Lorexys and Moderate Dose Lorexys of the present invention during the clinical trial did not lead to discontinuation and no depression, fainting, or accidents were observed.
A "Responder", as used herein, means a sexual desire Responder, one who improve by 2 points on the standard scale from 2-10. Responder is defined on the desire subscale of the Female Sexual Function Inventory; the subscale ranges from 2 (desire at very low or none and almost never or never) to 10 (desire at very high and almost always or always).
A "Remitter", as used herein is one whose score is at least 5.
Alternatively, a sexual distress Responder is one who improves by one point on the standard scale from 0 to 4. The measure is the "bothered by low sexual desire" item of the Female Sexual Distress Scale - Revised, and it ranges from 4, always, to 0, never, and a Remitter is one whose score is no higher than 2, occasionally.
In one aspect, the invention provides compositions and methods of treating a subject suffering from or susceptible to a sexual disorder or symptom thereof (e.g., HSDD, erectile disorder, sexual interest arousal disorder, FSD, MSD, and the like) comprising administering to a subject in need thereof a therapeutically effective amount of a composition delineated herein.
In one aspect, the invention provides a composition comprising a 5-HT2A
antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier. In another aspect the composition is that wherein the 5-HT2A antagonist is also a
Uniquely, the novel combination treatments of the present invention show unexpected superiority over the HSDD treatments for woman available heretofore in efficacy and/or inducing fewer or no side effects. In an HSDD clinical trial for premenopausal women to test safety and efficacy of the Moderate Dose Lorexys and the Low Dose Lorexys, in which standard measures of sexual desire and sexual distress were used, the percentage of women treated with Low Dose Lorexys and Moderate Dose Lorexys who met responder criteria were at about 76%
and about 88%, respectively. In contrast, only 36% and 45%, respectively, of the same women, who were treated with only bupropion SR at the same dosage strengths and in accordance with the same treatment regimens, met responder criteria.
These advantages of the present invention are not just highly statistically significant, p 0.01, they are highly unexpected. The % of women who met the criteria for remission on Low Dose Lorexys and Moderate Dose Lorexys showed similar advantage over bupropion treatment.
In addition, the Low Dose Lorexys and Moderate Dose Lorexys treatments of the present invention are also an advantage over prior treatments in how rapidly patients responded.
Remission typically takes at least 3 months with other treatments, but, with the Low Dose Lorexys and Moderate Dose Lorexys treatments of the present invention, about 58% of the treated women surprisingly met remission criteria within about 4 weeks.
As to side effects, the main side effects of concern to the FDA for drugs in this field have been related to over-sedation, i.e., somnolence, fatigue, dizziness, depression, accidents, and fainting, all of which worsen with alcohol. However, surprisingly and quite unexpected, no sedative-type side effect during the clinical trial was rated as severe for the women treated with the Low Dose Lorexys and Moderate Dose Lorexys of the present invention. Also quite surprising and unexpected, treatment of the women with the Low Dose Lorexys and Moderate Dose Lorexys of the present invention during the clinical trial did not lead to discontinuation and no depression, fainting, or accidents were observed.
A "Responder", as used herein, means a sexual desire Responder, one who improve by 2 points on the standard scale from 2-10. Responder is defined on the desire subscale of the Female Sexual Function Inventory; the subscale ranges from 2 (desire at very low or none and almost never or never) to 10 (desire at very high and almost always or always).
A "Remitter", as used herein is one whose score is at least 5.
Alternatively, a sexual distress Responder is one who improves by one point on the standard scale from 0 to 4. The measure is the "bothered by low sexual desire" item of the Female Sexual Distress Scale - Revised, and it ranges from 4, always, to 0, never, and a Remitter is one whose score is no higher than 2, occasionally.
In one aspect, the invention provides compositions and methods of treating a subject suffering from or susceptible to a sexual disorder or symptom thereof (e.g., HSDD, erectile disorder, sexual interest arousal disorder, FSD, MSD, and the like) comprising administering to a subject in need thereof a therapeutically effective amount of a composition delineated herein.
In one aspect, the invention provides a composition comprising a 5-HT2A
antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier. In another aspect the composition is that wherein the 5-HT2A antagonist is also a
5-HTIA receptor agonist. In another aspect the composition is that comprising trazodone and bupropion. In another aspect the composition is that comprising trazodone in a dosage range of 25-450 mg and bupropion in a dosage range of 200-450 mg. In another aspect the composition is that comprising trazodone in a dosage range of 25-450 mg and bupropion in a dosage range of 25-450 mg.
In one embodiment, the composition is that comprising bupropion, comprising bupropion in a dosage range of 200-450 mg; comprising bupropion in a dosage range of 225-300 mg; or comprising bupropion in a dosage range of 200-275 mg; comprising bupropion in a dosage range of 100-450 mg; comprising bupropion in a dosage range of 100-275 mg;
comprising bupropion in a dosage range of 25-275 mg; comprising bupropion in a dosage range of XX-YY mg, wherein XX is an integer between 5 and 400 and YY is an integer between 50 and 450.
In one embodiment, the composition is that comprising trazodone, comprising trazodone in a dosage range of 25-450 mg; comprising trazodone in a dosage range of 75-150 mg; or comprising trazodone in a dosage range of 50-100 mg; comprising trazodone in a dosage range of XX-YY mg, wherein XX is an integer between 25 and 400 and YY is an integer between 50 and 450.
In one aspect, the invention provides a method of treating a subject suffering from or susceptible to a hypoactive sexual desire disorder (HSDD) comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a 5-HT2A antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier. In one aspect, one compound is both a 5-HT2A antagonist and a 5-HTIA receptor agonist (e.g., trazodone). In another aspect, the norepinephrine-dopamine reuptake inhibitor is also a alpha adrenergic blocker (e.g., bupropion).
In one aspect, the invention provides a method of treating a subject suffering from or susceptible to a hypoactive sexual desire disorder (HSDD) comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a 5-HTIA receptor agonist, a 5-HT2A antagonist, and a pharmaceutically acceptable carrier. In one aspect, one compound is the 5-HTIA receptor agonist and the 5-HT2A antagonist (e.g., trazodone).
In aspects, the method is that wherein the sexual disorder (SD) is female sexual disorder (FSD).
In aspects, the method is that wherein the SD is female orgasm disorder (FOD);
wherein the SD
is female sexual arousal disorder (FSAD); or wherein the SD is sexual pain disorder or dysfunction. In aspects, the method is that wherein the FSD includes one or more simultaneous dysfunctions of sexual desire, arousal, orgasm, and/or pain. In aspects, the method is that wherein the SD is male sexual disorder (MSD).
Another aspect is a method of treating a disease, disorder or symptom thereof described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) in a subject comprising administering to the subject a compound or composition herein.
Another aspect is a method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a compound or composition herein.
Another aspect is a method of treating male HSDD in a subject comprising administering to the subject a compound or composition herein.
Another aspect is an extended release composition comprising a 5-HT2A
antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier.
In one aspect, the invention provides a composition comprising the 5-HTIA
receptor agonist and 5-HT2A antagonist nefazodone and a pharmaceutically acceptable carrier.
In one aspect, the invention provides a composition comprising the 5-HTIA
receptor agonist and 5-HT2A antagonist mirtazapine and a pharmaceutically acceptable carrier.
Other aspects include those, wherein the composition is administered orally;
wherein the composition is administered topically; wherein the subject is diagnosed and being treated for depression; wherein the subject is not undergoing treatment for depression;
wherein the subject is concurrently prescribed an additional therapeutic agent; or wherein the subject is concurrently not prescribed an additional therapeutic agent; wherein the subject is concurrently administered an additional therapeutic agent; or wherein the subject is concurrently not administered an additional therapeutic agent.
In one aspect, the invention provides a composition comprising a 5-HTIA
receptor agonist, a 5-HT2A antagonist, and a pharmaceutically acceptable carrier.
In one embodiment, the composition is that comprising bupropion, comprising bupropion in a dosage range of 100-450 mg qd; comprising bupropion in a dosage range of 200-450 mg qd;
comprising bupropion in a dosage range of 100-300 mg qd; comprising bupropion in a dosage range of 225-300 mg qd; comprising bupropion in a dosage range of 100-275 mg qd; or comprising bupropion in a dosage range of 200-275 mg qd; comprising bupropion in a dosage range of XX-YY mg qd, wherein XX is an integer between 5 and 400 and YY is an integer between 50 and 450.
In one embodiment, the composition is that comprising trazodone, comprising trazodone in a dosage range of 25-450 mg qd; comprising trazodone in a dosage range of 75-150 mg qd; or comprising trazodone in a dosage range of 50-100 mg qd; comprising trazodone in a dosage range of XX-YY mg qd, wherein XX is an integer between 25 and 400 and YY is an integer between 50 and 450.
In one embodiment, the composition is that comprising bupropion and trazodone, comprising bupropion in a dosage range of 50-450 mg and trazodone in a dosage range of 25-450 mg;
comprising bupropion in a dosage range of 200-450 mg and trazodone in a dosage range of 25-450 mg; comprising bupropion in a dosage range of 100-300 mg qd and comprising trazodone in a dosage range of 75-150 mg qd; comprising bupropion in a dosage range of 225-300 mg qd and comprising trazodone in a dosage range of 75-150 mg qd; comprising bupropion in a dosage range of 100-275 mg qd and comprising trazodone in a dosage range of 50-100 mg qd; or comprising bupropion in a dosage range of 200-275 mg qd and comprising trazodone in a dosage range of 50-100 mg qd.
In one aspect, the invention provides a method of making a composition comprising combining a 5-HT2A antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier. In one aspect, the invention provides a method of making a composition comprising combining a 5-HTIA receptor agonist, 5-HT2A antagonist, and a pharmaceutically acceptable carrier. In one aspect, the invention provides a method of making a composition comprising combining a 5-HTIA receptor agonist, and a pharmaceutically acceptable carrier. In one aspect, the invention provides a method of making a composition comprising combining a 5-HTIA antagonist, and a pharmaceutically acceptable carrier.
In one aspect, the method of making a composition comprises combining a 5-HTIA
receptor agonist, a norepinephrine-dopamine reuptake inhibitor and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 of a 5-HTIA receptor agonist. In another aspect, the method of making comprises combining a 5-HT2A antagonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 mg of a 5-HT2A
antagonist and a norepinephrine-dopamine reuptake inhibitor.
In one embodiment, the method comprises combining bupropion, trazodone, and a pharmaceutically acceptable carrier.
In one aspect, the invention provides a kit comprising a composition delineated herein and a label providing instructions for administration of the composition to a subject for treating or ameliorating HSDD or symptoms thereof in the subject.
In another aspect, the invention provides a method of treating hypoactive sexual desire disorder (HSDD) in a subject comprising administering to the subject a 5-HTiA receptor agonist, and a 5-HT2A antagonist. The methods herein can further comprise those wherein the subject is identified as in need of such treatment, and those wherein the subject is treated upon administration of the compounds and/or compositions herein. The methods can include those wherein the subject has not previously been administered the compounds and/or compositions herein, or wherein the subject has not previously been administered the compounds and/or compositions herein at the stated dosage levels or administration regimens.
In another embodiment, the invention a method of treating a subject suffering from or susceptible to a hypoactive sexual desire disorder (HSDD) comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising any one of a 5-HT2A antagonist, a norepinephrine-dopamine reuptake inhibitor, a 5-HTIA
receptor agonist, an endocrine active agent, or any combination thereof and a pharmaceutically acceptable carrier.
In another aspect, the invention provides a method of treating hypoactive sexual desire disorder (HSDD) in a subject comprising administering to the subject a therapeutically effective amount of any one of a 5-HT2A antagonist, a norepinephrine-dopamine reuptake inhibitor, a 5-HTIA
receptor agonist, an endocrine active agent, or any combination thereof.
In aspects the endocrine agent is testosterone, which can be in an amount of a dosage range of 25 to 1000 mg.
In aspects, the subject is that wherein the subject is not being treated with a selective serotonin reuptake inhibitor (SSRI) agent.
In aspects, the subject is that wherein the subject is being treated with a selective serotonin reuptake inhibitor (S SRI) agent.
In aspects, the subject is that wherein the subject is identified as having selective serotonin reuptake inhibitor (SSRI) agent induced HSDD.
In aspects, the subject is that wherein the subject is being treated with a PDE-5 inhibitor compound (i.e., sildenafil, tadalafil, and the like).
In aspects, the subject is that wherein the subject is not concurrently being treated with a PDE-5 inhibitor compound (i.e., sildenafil, tadalafil, and the like).
In aspects, the subject is that wherein the subject is being treated with an endocrine agent (e.g., testosterone).
In aspects, the subject is that wherein the subject is not concurrently being treated with an endocrine agent (e.g., testosterone).
In another aspect, the methods herein comprise taking a sample (i.e., fluid, blood, urine, saliva, tissue, etc.) and assessing a biological marker (i.e., liver enzymes, CYP3A4, and/or a genetic marker of the transport, receptor type, receptor density, receptor affinity, metabolism, or activity of serotonin, serotonin lA or 2A subtype, dopamine, or a receptor subtype of dopamine) to measure health status of the subject either prior to, during or after administration of the compositions herein.
Brief Description of the Figures The foregoing and other objects, advantages and features of the present invention, and the manner in which the same are accomplished, will become more readily apparent upon consideration of the following detailed description of the invention taken in conjunction with the accompanying figures and example, which illustrate embodiments, wherein:
FIG. 1 summarizes the results of a Phase ha 3-way open label cross-over study in which proprietary combinations of trazodone and bupropion were used to treat premenopausal women for hypoactive sexual desire disorder (HSDD);
FIG. 2 summarizes the design and doses of the Phase ha 3-way open label cross-over study;
FIG. 3 summarizes the entry criteria: inclusions of the Phase Ha 3-way open label cross-over study;
FIG. 4 summarizes the entry criteria: exclusions of the Phase Ha 3-way open label cross-over study;
FIG. 5 depicts a graph showing sample size: 30 for > 80% power to detect a delta of 35%
between control (bupropion) and Low Dose Lorexys and Moderate Dose Lorexys of the Phase ha 3-way open label cross-over study;
FIG. 6 summarizes the dispositions of the patients in the of the Phase ha 3-way open label cross-over study;
FIG. 7 summarizes the % responders for Moderate Dose Lorexys vs Bupropion of the Phase Ha 3-way open label cross-over study;
FIG. 8 summarizes the % of patients reaching remission for Low Dose Lorexys vs Bupropion of the Phase Ha 3-way open label cross-over study;
FIG. 9 summarizes Low Dose Lorexys intermediate efficacy as to patients' global impression of change, that is, % improved, for all those patients with an end of study evaluation of the Phase Ha 3-way open label cross-over study;
FIG. 10 summarizes the adverse events of the Phase ha 3-way open label cross-over study; and FIG. 11 summarizes the conclusions of the Phase Ha 3-way open label cross-over study.
Detailed Description of the Invention The present inventors have now discovered a therapeutic strategy that addresses hypoactive sexual desire disorder (HSDD) in a woman and, in particular, a pre-menopausal woman.
The present invention relates, at least in part, to the discovery that a combination of a 5-HT2A
antagonist (which is optionally a 5-HTIA receptor agonist), a norepinephrine-dopamine reuptake inhibitor, (and optionally an endocrine active agent) provides unexpected superior and synergistic results in addressing hypoactive sexual desire disorder (HSDD) in a subject.
1. Definitions Before further description of the present invention, and in order that the invention may be more readily understood, certain terms are first defined and collected here for convenience.
The term "administration" or "administering" includes routes of introducing the compound of the invention(s) to a subject to perform their intended function. Examples of routes of administration that may be used include injection (subcutaneous, intravenous, parenterally, intraperitoneally, intrathecal), oral, buccal, sublingual, inhalation, rectal and transdermal.
The pharmaceutical preparations may be given by forms suitable for each administration route. For example, these preparations are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred. The injection can be bolus or can be continuous infusion. Depending on the route of administration, the compound of the invention can be coated with or disposed in a selected material to protect it from natural conditions which may detrimentally effect its ability to perform its intended function. The compound of the invention can be administered alone, or in conjunction with either another agent as described above or with a pharmaceutically-acceptable carrier, or both. The compound of the invention can be administered prior to the administration of the other agent, simultaneously with the agent, or after the administration of the agent.
Furthermore, the compound of the invention can also be administered in a pro-drug form which is converted into its active metabolite, or more active metabolite in vivo.
The language "biological activities" of a compound of the invention includes all activities elicited by compound of the inventions in a responsive cell. It includes genomic and non-genomic activities elicited by these compounds.
"Biological composition" or "biological sample" refers to a composition containing or derived from cells or biopolymers. Cell-containing compositions include, for example, mammalian blood, red cell concentrates, platelet concentrates, leukocyte concentrates, blood cell proteins, blood plasma, platelet-rich plasma, a plasma concentrate, a precipitate from any fractionation of the plasma, a supernatant from any fractionation of the plasma, blood plasma protein fractions, purified or partially purified blood proteins or other components, serum, semen, mammalian colostrum, milk, saliva, placental extracts, a cryoprecipitate, a cryosupernatant, a cell lysate, mammalian cell culture or culture medium, products of fermentation, ascites fluid, proteins induced in blood cells, and products produced in cell culture by normal or transformed cells (e.g., via recombinant DNA or monoclonal antibody technology). Biological compositions can be cell-free. In a preferred embodiment, a suitable biological composition or biological sample is a red blood cell suspension. In some embodiments, the blood cell suspension includes mammalian blood cells. Preferably, the blood cells are obtained from a human, a non-human primate, a dog, a cat, a horse, a cow, a goat, a sheep or a pig. In preferred embodiments, the blood cell suspension includes red blood cells and/or platelets and/or leukocytes and/or bone marrow cells.
The term "effective amount" includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result, e.g., sufficient to treat a hypoactive sexual desire disorder in a subject. An effective amount of compound of the invention may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound of the invention to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the compound of the invention are outweighed by the therapeutically beneficial effects.
A therapeutically effective amount of compound of the invention (i.e., an effective dosage) may range from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.
The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present.
Moreover, treatment of a subject with a therapeutically effective amount of a compound of the invention can include a single treatment or, preferably, can include a series of treatments. In one example, a subject is treated with a compound of the invention in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of a compound of the invention used for treatment may increase or decrease over the course of a particular treatment. Administration regimens herein where designated are in accordance with the following abbreviations: SID or QD=Once a day; BID=Twice a day, TID=Three times a day; QID=Four times a day;
q.h.s=every night.
The term "homeostasis" is art-recognized to mean maintenance of static, or constant, conditions in an internal environment.
The language "improved biological properties" refers to any activity inherent in a compound of the invention that enhances its effectiveness in vivo. In a preferred embodiment, this term refers to any qualitative or quantitative improved therapeutic property of a compound of the invention, such as reduced toxicity.
The term "modulate" refers to an increase or decrease, e.g., the alteration in hypoactive sexual desire disorder and/or symptoms thereof in a subject such that a desired end result is achieved, e.g., a therapeutic result.
The term "obtaining" as in "obtaining a compound useful in treating hypoactive sexual desire disorder" is intended to include purchasing, synthesizing or otherwise acquiring the compound.
The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
The language "a prophylactically effective amount" of a compound refers to an amount of a compound of the invention any formula herein or otherwise described herein which is effective, upon single or multiple dose administration to the patient, in preventing or treating a sexual disorder.
The language "reduced toxicity" is intended to include a reduction in any undesired side effect elicited by a compound of the invention when administered in vivo.
The term "subject" includes organisms which are capable of suffering from a sexual disorder or who could otherwise benefit from the administration of a compound or composition of the invention, such as human (male or female) and non-human animals (male or female). Preferred humans include human patients suffering from or prone to suffering from hypoactive sexual desire disorder or associated state, as described herein. The term "non-human animals" of the invention includes all vertebrates, e.g., mammals, e.g., rodents, e.g., mice, and non-mammals, such as non-human primates, e.g., sheep, dog, cow, chickens, amphibians, reptiles, etc.
The term "susceptible to a hypoactive sexual desire disorder" is meant to include subjects at risk of developing hypoactive sexual desire disorder, e.g., subjects previously diagnosed as having or having a family or medical history of hypoactive sexual desire disorder, and the like.
The phrases "systemic administration, "administered systemically", "peripheral administration"
and "administered peripherally" as used herein mean the administration of a compound of the invention(s), drug or other material, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
The language "therapeutically effective amount" of a compound of the invention of the invention refers to an amount of an agent which is effective, upon single or multiple dose administration to the patient, in modulating hypoactive sexual desire disorder and/or symptoms of hypoactive sexual desire disorder, or in improving the patient (either objectively or subjectively according to the patient or health care provider) beyond that expected in the absence of such treatment.
2. Compounds of the Invention In one aspect, the invention provides compounds capable of modulating hypoactive sexual desire disorder in a subject. Such compounds include a 5-HT2A antagonist, a 5-HTIA
receptor agonist, a norepinephrine-dopamine reuptake inhibitor, and an endocrine active agent.
Compositions of the invention further include a pharmaceutically acceptable carrier.
The compounds delineated herein include a 5-HT2A antagonist, that is a compound that demonstrates antagonistic activity against the 5-HT2A receptor; a norepinephrine-dopamine reuptake inhibitor; that is a compound that exhibits inhibition activity in norepinephrine-dopamine reuptake; a 5-HTIA receptor agonist, that is a compound that demonstrates agonist activity against the 5-HTIA receptor; and an endocrine active agent, that is an agent that is active in modulating the endocrine system.
In one embodiment, the invention provides a compound (e.g., a compound herein) capable of modulating hypoactive sexual desire disorder; and pharmaceutically acceptable esters, salts, hydrates, solvates, isomers and prodrugs thereof Naturally occurring or synthetic isomers can be separated in several ways known in the art.
Methods for separating a racemic mixture of two enantiomers include chromatography using a chiral stationary phase (see, e.g., "Chiral Liquid Chromatography," W. J.
Lough, Ed. Chapman and Hall, New York (1989)). Enantiomers can also be separated by classical resolution techniques. For example, formation of diastereomeric salts and fractional crystallization can be used to separate enantiomers. For the separation of enantiomers of carboxylic acids, the diastereomeric salts can be formed by addition of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, and the like. Alternatively, diastereomeric esters can be formed with enantiomerically pure chiral alcohols such as menthol, followed by separation of the diastereomeric esters and hydrolysis to yield the free, enantiomerically enriched carboxylic acid.
For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.
3. Uses Of The Compounds of the Invention In one embodiment, the invention provides methods of treating hypoactive sexual desire disorder (HSDD) in a subject comprising administering to the subject a composition delineated herein. In certain embodiments, the subject is a mammal, e.g., a primate, e.g., a human.
In aspect, the disease, disorder or symptom thereof in which the compounds, compositions, and methods of treatment relate to is one described in the Diagnostic and Statistical Manual of Mental Disorders 4th edition--Text Revision, (DSM-I-TRV), American Psychiatric Association.
In certain embodiments, the methods of the invention include administering to a subject a therapeutically effective amount of a compound of the invention in combination with another pharmaceutically active compound. Examples of pharmaceutically active compounds include compounds known to treat hypoactive sexual desire disorder (HSDD) in a subject. Other pharmaceutically active compounds that may be used can be found in Harrison's Principles of Internal Medicine, Thirteenth Edition, Eds. T. R. Harrison et al. McGraw-Hill N.Y., NY; and the Physicians Desk Reference 50th Edition 1997, Oradell N.J., Medical Economics Co., the complete contents of which are expressly incorporated herein by reference. The compound of the invention and the pharmaceutically active compound may be administered to the subject in the same pharmaceutical composition or in different pharmaceutical compositions (at the same time or at different times).
Determination of a therapeutically effective hypoactive sexual desire disorder (HSDD) effective amount, a prophylactically effective hypoactive sexual desire disorder amount of the compound of the invention, can be readily made by the physician or veterinarian (the "attending clinician"), as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances. The dosages may be varied depending upon the requirements of the patient in the judgment of the attending clinician; the severity of the condition being treated and the particular compound being employed. In determining the therapeutically effective hypoactive sexual desire disorder amount or dose, and the prophylactically effective hypoactive sexual desire disorder amount or dose, a number of factors are considered by the attending clinician, including, but not limited to: the specific hypoactive sexual desire disorder involved;
pharmacodynamic characteristics of the particular agent and its mode and route of administration; the desired time course of treatment; the species of mammal;
its size, age, and general health; the specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the kind of concurrent treatment (i.e., the interaction of the compound of the invention with other co-administered therapeutics); and other relevant circumstances.
The dosage administration can be in a single dosage form or multiple dosage forms. The dosages can be administered concurrently, simultaneously, or sequentially. The dosages can be a single dosage immediately prior to sexual activity, or can be one or more doses daily without regard to timing prior to sexual activity. Treatment can be initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage may be increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. A
therapeutically effective amount and a prophylactically effective amount of a compound of the invention of the invention is expected to vary from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 100 mg/kg/day.
The identification of those patients who are in need of prophylactic treatment for hypoactive sexual desire disorder is well within the ability and knowledge of one skilled in the art. Certain of the methods for identification of patients which are at risk of developing hypoactive sexual desire disorder which can be treated by the subject method are appreciated in the medical arts, such as family history, and the presence of risk factors associated with the development of that disease state in the subject patient (e.g., use of antidepressant drugs, hormonal contraceptives, antihormonal and/or cytotoxic chemotherapies, sedatives, antipsychotic drugs, antiepileptic drugs, mood stabilizer drugs, opioid drugs, alcohol, or narcotic drugs). A
clinician skilled in the art can readily identify such candidate patients, by the use of, for example, clinical tests, physical examination and medical/family history.
As used herein, "obtaining a biological sample from a subject," includes obtaining a sample for use in the methods described herein. A biological sample is described above.
In another aspect, a compound of the invention is packaged in a therapeutically effective amount with a pharmaceutically acceptable carrier or diluent. The composition may be formulated for treating a subject suffering from or susceptible to a hypoactive sexual desire disorder, and packaged with instructions to treat a subject suffering from or susceptible to a hypoactive sexual desire disorder.
The subject may be at risk of a hypoactive sexual desire disorder, may be exhibiting symptoms of a hypoactive sexual desire disorder, may be susceptible to a hypoactive sexual desire disorder and/or may have been diagnosed with a sexual desire disorder.
If the modulation of the status indicates that the subject may have a favorable clinical response to the treatment, the subject may be treated with the compound. For example, the subject can be administered therapeutically effective dose or doses of the compound.
Kits of the invention include kits for treating a hypoactive sexual desire disorder in a subject.
The kit may include a compound of the invention, for example, a compound described herein, pharmaceutically acceptable esters, salts, and prodrugs thereof, and instructions for use. The instructions for use may include information on dosage, method of delivery, storage of the kit, etc. In aspects, the kits (and methods of using them) comprise instructions indicating that the compositions and/or treatment methods are contraindicated for (or not to be administered to) subjects that: (1) require and/or are taking CYP3A4, CYP 2B6-, or CYP 2D6-metabolized drugs;
(ii) take any sex hormone other than an approved hormonal contraceptive; (iii) drink more than one alcoholic drink per day (e.g., 12-oz beer, 4-oz wine, etc).
Alternatively, the effects of compound of the invention can be characterized in vivo using animals models.
4. Pharmaceutical Compositions The invention also provides a pharmaceutical composition, comprising an effective amount of a compound described herein and a pharmaceutically acceptable carrier. In a further embodiment, the effective amount is effective to treat a hypoactive sexual desire disorder, as described previously.
In an embodiment, the compound of the invention is administered to the subject using a pharmaceutically-acceptable formulation, e.g., a pharmaceutically-acceptable formulation that provides sustained delivery of the compound of the invention to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.
In certain embodiments, these pharmaceutical compositions are suitable for topical or oral, buccal or sublingual administration to a subject. In other embodiments, as described in detail below, the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) topical application, for example, as a cream, ointment or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; or (5) aerosol, for example, as an aqueous aerosol, liposomal preparation or solid particles containing the compound or composition herein.
The phrase "pharmaceutically acceptable" refers to those compound of the inventions of the present invention, compositions containing such compounds, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The phrase "pharmaceutically-acceptable carrier" includes pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body. Each carrier is "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch;
(3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc;
(8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
Compositions containing a compound of the invention(s) include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, more preferably from about 10 percent to about 30 percent.
Methods of preparing these compositions include the step of bringing into association a compound of the invention(s) with the carrier and, optionally, one or more accessory ingredients.
In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
Compositions of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, caplets, gel caps, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the invention(s) as an active ingredient. A compound may also be administered as a bolus, electuary or paste.
In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
Liquid dosage forms for oral administration of the compound of the invention(s) include pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
In addition to inert diluents, the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
Suspensions, in addition to the active compound of the invention(s) may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof Pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compound of the invention(s) with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.
Compositions of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
Dosage forms for the topical or transdermal administration of a compound of the invention(s) include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound of the invention(s) may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
The ointments, pastes, creams and gels may contain, in addition to compound of the invention(s) of the present invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to a compound of the invention(s), excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
The compound of the invention(s) can be alternatively administered by aerosol.
This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound. A nonaqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers are preferred because they minimize exposing the agent to shear, which can result in degradation of the compound.
Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of the agent together with conventional pharmaceutically-acceptable carriers and stabilizers, The carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aerosols generally are prepared from isotonic solutions.
Transdermal patches have the added advantage of providing controlled delivery of a compound of the invention(s) to the body. Such dosage forms can be made by dissolving or dispersing the agent in the proper medium. Absorption enhancers can also be used to increase the flux of the active ingredient across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active ingredient in a polymer matrix or gel.
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of the invention.
Pharmaceutical compositions of the invention suitable for parenteral administration comprise one or more compound of the invention(s) in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
Examples of suitable aqueous and nonaqueous carriers, which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions.
In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsule matrices of compound of the invention(s) in biodegradable polymers such as polylactide-polyglycolide.
Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemuisions which are compatible with body tissue.
When the compound of the invention(s) are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically-acceptable carrier.
Regardless of the route of administration selected, the compound of the invention(s), which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
Actual dosage levels and time course of administration of the active ingredients in the pharmaceutical compositions of the invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. An exemplary dose range is from 0.1 to 10 mg per day.
A preferred dose of the compound of the invention for the present invention is the maximum that a patient can tolerate and not develop serious side effects. Preferably, the compound of the invention of the present invention is administered at a concentration of about 0.001 mg to about 100 mg per kilogram of body weight, about 0.001--about 10 mg/kg or about 0.001 mg--about 100 mg/kg of body weight. Ranges intermediate to the above-recited values are also intended to be part of the invention.
5. Example The invention is further illustrated by the following example which is intended to illustrate but not limit the scope of the invention.
Low Dose Lorexys and High Dose Lorexys HSDD Clinical Study in Premenopausal Women We sought to estimate the prevalence of low sexual desire and hypoactive sexual desire disorder (HSDD) in US women, focusing on their menopausal status.
Methods:
An open cross-sectional study was performed. From a probability sample of households, 2207 US women aged 30 to 70 years and in stable relationships (>or=3 months) were interviewed by telephone. The analysis focused on 755 premenopausal women and 552 naturally and 637 surgically menopausal women. Low sexual desire was defined using the Profile of Female Sexual Function desire domain, and HSDD was defined using the Profile of Female Sexual Function and the Personal Distress Scale.
Results:
Prevalence of low sexual desire ranged from 26.7% among premenopausal women to 52.4%
among naturally menopausal women. The prevalence of HSDD was highest among surgically menopausal women (12.5%). Compared with premenopausal women and adjusting for age, race/ethnicity, educational level, and smoking status, the prevalence ratios for HSDD were 2.3 (95% confidence interval, 1.2-4.5) for surgically menopausal women and 1.2 (0.5-2.8) for naturally menopausal women; the prevalence ratios for low sexual desire were 1.3 (0.9-1.9) and 1.5 (1.0-2.2) for surgically and naturally menopausal women, respectively.
Conclusions:
Prevalence of low sexual desire is elevated among surgically and naturally menopausal women vs premenopausal women. Distress about low desire (HSDD) appears to be more than twice as prevalent among surgically menopausal women vs premenopausal women, although the estimate is fairly imprecise.
Hyposexual desire disorder {HSDD) remains without approved pharmacotherapies, though one CNS agent, bupropion, is recommended. This study tested the efficacy and safety of Lorexys, a proprietary combination of bupropion and trazodone, in premenopausal women.
A clinical study was conducted with Lorexys to treat premenopausal women for HSDD. The study's primary objective was to evaluate Lorexys' safety, tolerability and pro-sexual efficacy as compared to bupropion, one of its constituent drugs. Other objectives included exploration of the onset and duration of action of Lorexys.
The study had an adaptive, three-way crossover, open-label design. It enrolled 30 premenopausal women who met the DSM-IV-TR criteria for HSDD, and it also assessed patients for the newly defined DSM-5 Sexual Interest and Arousal Disorder. Each subject received a daily dose of bupropion as an active control for four weeks followed by a week-long washout period, then daily administration of a low dose of Lorexys for four weeks followed by another washout period, and, finally, a moderate dose of Lorexys for four weeks followed by another washout period.
The dosing and treatment regimens for the study were as follows:
Active Control: Bupropion SR 300 mg was administered once daily in the morning for four weeks.
Low Dose Lorexys: Low dose Lorexys is combination therapy that consists of two drugs: buproprion and trazadone. burpropion SR 150 mg was administered once daily in the morning and trazadone ER 75 mg was administered once daily at bedtime, each for four weeks.
Moderate Dose Lorexys: Moderate dose Lorexys is also combination therapy that consist of two drugs: buproprion and trazadone. burpropion SR 150 mg was administered twice daily, once in the morning and once eight (8) hours later, and trazadone ER
150 mg was administered once daily at bedtime, each for four weeks.
Patients self-evaluated weekly with questionnaires and were assessed during eight clinic visits.
Outcome measures for efficacy included validated self-rated scales of Sexual Function and Sexual Distress and global change. Outcome measures for safety included comprehensive evaluations of symptoms and vital signs, plus standard laboratory studies and electrocardiograms. The study was conducted at two clinical sites in the U.S.
Materials and Methods:
This was an open-label crossover study in non-depressed, otherwise healthy patients with DSM-IV-TR HSDD, aged 25-50 years, with four weeks per treatment. With n=30 and 33%
more Lorexys responders vs. Bupropion SR, the power at a =0.05 was 80%. Four weeks of Bupropion SR at 300 mg/day and a washout was followed by four weeks of Lorexys low-dose (LOR-low), i.e, Bupropion SR plus Trazodone ER at doses lower than the labeled doses, followed by another washout and four weeks of Lorexys moderate-dose (LORmod; 2x LOR-low).The primary efficacy endpoint was Female Sexual Function Index Desire domain (FSFI-d); the key secondary was Female Sexual Distress Scale-Revised (FSDS-R). Analyses included %
responders and %
remitters from the first baseline, using standard definitions (see Table 1) for FSFI-d and FSDS-R
item 13 (FSDS-R-i13), plus Patient's Global Impression of Change (PGIC). See FIGS. 1-11.
Results Five patients (17%) discontinued for administrative reasons; one (4%) discontinued for adverse events, on LOR-mod. Table 1 below shows responder and remitter rates with LOR-mod; rates with LOR-low were intermediate and non-significant vs. bupropion.
Conclusion Lorexys was highly superior to bupropion in non-depressed, otherwise healthy, premenopausal HSDD to Bupropion SR alone in the treatment of premenopausal women for HSDD. See Table 1 and FIGS. 1-11.
Table 1. Results Measure Definition LOR-mod Bupropion p-value on Fisher's Exact test, 2-tailed Responders FSFI-d 2-point increase 76% 38% <0.01 FSDS-R-i13 1-point decrease 88% 45% <0.01 PGIC >=Moderately 58% 24% <0.05 Improved Remitters FSFI-d >=5 58% 24% <0.05 FSDS-R-i13 <=2 75% 32% <0.01 The disclosures of each and every patent, patent application and publication cited herein are hereby incorporated herein by reference in their entireties.
The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
Although the invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of the invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The claims are intended to be construed to include all such embodiments and equivalent variations.
In one embodiment, the composition is that comprising bupropion, comprising bupropion in a dosage range of 200-450 mg; comprising bupropion in a dosage range of 225-300 mg; or comprising bupropion in a dosage range of 200-275 mg; comprising bupropion in a dosage range of 100-450 mg; comprising bupropion in a dosage range of 100-275 mg;
comprising bupropion in a dosage range of 25-275 mg; comprising bupropion in a dosage range of XX-YY mg, wherein XX is an integer between 5 and 400 and YY is an integer between 50 and 450.
In one embodiment, the composition is that comprising trazodone, comprising trazodone in a dosage range of 25-450 mg; comprising trazodone in a dosage range of 75-150 mg; or comprising trazodone in a dosage range of 50-100 mg; comprising trazodone in a dosage range of XX-YY mg, wherein XX is an integer between 25 and 400 and YY is an integer between 50 and 450.
In one aspect, the invention provides a method of treating a subject suffering from or susceptible to a hypoactive sexual desire disorder (HSDD) comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a 5-HT2A antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier. In one aspect, one compound is both a 5-HT2A antagonist and a 5-HTIA receptor agonist (e.g., trazodone). In another aspect, the norepinephrine-dopamine reuptake inhibitor is also a alpha adrenergic blocker (e.g., bupropion).
In one aspect, the invention provides a method of treating a subject suffering from or susceptible to a hypoactive sexual desire disorder (HSDD) comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a 5-HTIA receptor agonist, a 5-HT2A antagonist, and a pharmaceutically acceptable carrier. In one aspect, one compound is the 5-HTIA receptor agonist and the 5-HT2A antagonist (e.g., trazodone).
In aspects, the method is that wherein the sexual disorder (SD) is female sexual disorder (FSD).
In aspects, the method is that wherein the SD is female orgasm disorder (FOD);
wherein the SD
is female sexual arousal disorder (FSAD); or wherein the SD is sexual pain disorder or dysfunction. In aspects, the method is that wherein the FSD includes one or more simultaneous dysfunctions of sexual desire, arousal, orgasm, and/or pain. In aspects, the method is that wherein the SD is male sexual disorder (MSD).
Another aspect is a method of treating a disease, disorder or symptom thereof described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) in a subject comprising administering to the subject a compound or composition herein.
Another aspect is a method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a compound or composition herein.
Another aspect is a method of treating male HSDD in a subject comprising administering to the subject a compound or composition herein.
Another aspect is an extended release composition comprising a 5-HT2A
antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier.
In one aspect, the invention provides a composition comprising the 5-HTIA
receptor agonist and 5-HT2A antagonist nefazodone and a pharmaceutically acceptable carrier.
In one aspect, the invention provides a composition comprising the 5-HTIA
receptor agonist and 5-HT2A antagonist mirtazapine and a pharmaceutically acceptable carrier.
Other aspects include those, wherein the composition is administered orally;
wherein the composition is administered topically; wherein the subject is diagnosed and being treated for depression; wherein the subject is not undergoing treatment for depression;
wherein the subject is concurrently prescribed an additional therapeutic agent; or wherein the subject is concurrently not prescribed an additional therapeutic agent; wherein the subject is concurrently administered an additional therapeutic agent; or wherein the subject is concurrently not administered an additional therapeutic agent.
In one aspect, the invention provides a composition comprising a 5-HTIA
receptor agonist, a 5-HT2A antagonist, and a pharmaceutically acceptable carrier.
In one embodiment, the composition is that comprising bupropion, comprising bupropion in a dosage range of 100-450 mg qd; comprising bupropion in a dosage range of 200-450 mg qd;
comprising bupropion in a dosage range of 100-300 mg qd; comprising bupropion in a dosage range of 225-300 mg qd; comprising bupropion in a dosage range of 100-275 mg qd; or comprising bupropion in a dosage range of 200-275 mg qd; comprising bupropion in a dosage range of XX-YY mg qd, wherein XX is an integer between 5 and 400 and YY is an integer between 50 and 450.
In one embodiment, the composition is that comprising trazodone, comprising trazodone in a dosage range of 25-450 mg qd; comprising trazodone in a dosage range of 75-150 mg qd; or comprising trazodone in a dosage range of 50-100 mg qd; comprising trazodone in a dosage range of XX-YY mg qd, wherein XX is an integer between 25 and 400 and YY is an integer between 50 and 450.
In one embodiment, the composition is that comprising bupropion and trazodone, comprising bupropion in a dosage range of 50-450 mg and trazodone in a dosage range of 25-450 mg;
comprising bupropion in a dosage range of 200-450 mg and trazodone in a dosage range of 25-450 mg; comprising bupropion in a dosage range of 100-300 mg qd and comprising trazodone in a dosage range of 75-150 mg qd; comprising bupropion in a dosage range of 225-300 mg qd and comprising trazodone in a dosage range of 75-150 mg qd; comprising bupropion in a dosage range of 100-275 mg qd and comprising trazodone in a dosage range of 50-100 mg qd; or comprising bupropion in a dosage range of 200-275 mg qd and comprising trazodone in a dosage range of 50-100 mg qd.
In one aspect, the invention provides a method of making a composition comprising combining a 5-HT2A antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier. In one aspect, the invention provides a method of making a composition comprising combining a 5-HTIA receptor agonist, 5-HT2A antagonist, and a pharmaceutically acceptable carrier. In one aspect, the invention provides a method of making a composition comprising combining a 5-HTIA receptor agonist, and a pharmaceutically acceptable carrier. In one aspect, the invention provides a method of making a composition comprising combining a 5-HTIA antagonist, and a pharmaceutically acceptable carrier.
In one aspect, the method of making a composition comprises combining a 5-HTIA
receptor agonist, a norepinephrine-dopamine reuptake inhibitor and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 of a 5-HTIA receptor agonist. In another aspect, the method of making comprises combining a 5-HT2A antagonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 mg of a 5-HT2A
antagonist and a norepinephrine-dopamine reuptake inhibitor.
In one embodiment, the method comprises combining bupropion, trazodone, and a pharmaceutically acceptable carrier.
In one aspect, the invention provides a kit comprising a composition delineated herein and a label providing instructions for administration of the composition to a subject for treating or ameliorating HSDD or symptoms thereof in the subject.
In another aspect, the invention provides a method of treating hypoactive sexual desire disorder (HSDD) in a subject comprising administering to the subject a 5-HTiA receptor agonist, and a 5-HT2A antagonist. The methods herein can further comprise those wherein the subject is identified as in need of such treatment, and those wherein the subject is treated upon administration of the compounds and/or compositions herein. The methods can include those wherein the subject has not previously been administered the compounds and/or compositions herein, or wherein the subject has not previously been administered the compounds and/or compositions herein at the stated dosage levels or administration regimens.
In another embodiment, the invention a method of treating a subject suffering from or susceptible to a hypoactive sexual desire disorder (HSDD) comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising any one of a 5-HT2A antagonist, a norepinephrine-dopamine reuptake inhibitor, a 5-HTIA
receptor agonist, an endocrine active agent, or any combination thereof and a pharmaceutically acceptable carrier.
In another aspect, the invention provides a method of treating hypoactive sexual desire disorder (HSDD) in a subject comprising administering to the subject a therapeutically effective amount of any one of a 5-HT2A antagonist, a norepinephrine-dopamine reuptake inhibitor, a 5-HTIA
receptor agonist, an endocrine active agent, or any combination thereof.
In aspects the endocrine agent is testosterone, which can be in an amount of a dosage range of 25 to 1000 mg.
In aspects, the subject is that wherein the subject is not being treated with a selective serotonin reuptake inhibitor (SSRI) agent.
In aspects, the subject is that wherein the subject is being treated with a selective serotonin reuptake inhibitor (S SRI) agent.
In aspects, the subject is that wherein the subject is identified as having selective serotonin reuptake inhibitor (SSRI) agent induced HSDD.
In aspects, the subject is that wherein the subject is being treated with a PDE-5 inhibitor compound (i.e., sildenafil, tadalafil, and the like).
In aspects, the subject is that wherein the subject is not concurrently being treated with a PDE-5 inhibitor compound (i.e., sildenafil, tadalafil, and the like).
In aspects, the subject is that wherein the subject is being treated with an endocrine agent (e.g., testosterone).
In aspects, the subject is that wherein the subject is not concurrently being treated with an endocrine agent (e.g., testosterone).
In another aspect, the methods herein comprise taking a sample (i.e., fluid, blood, urine, saliva, tissue, etc.) and assessing a biological marker (i.e., liver enzymes, CYP3A4, and/or a genetic marker of the transport, receptor type, receptor density, receptor affinity, metabolism, or activity of serotonin, serotonin lA or 2A subtype, dopamine, or a receptor subtype of dopamine) to measure health status of the subject either prior to, during or after administration of the compositions herein.
Brief Description of the Figures The foregoing and other objects, advantages and features of the present invention, and the manner in which the same are accomplished, will become more readily apparent upon consideration of the following detailed description of the invention taken in conjunction with the accompanying figures and example, which illustrate embodiments, wherein:
FIG. 1 summarizes the results of a Phase ha 3-way open label cross-over study in which proprietary combinations of trazodone and bupropion were used to treat premenopausal women for hypoactive sexual desire disorder (HSDD);
FIG. 2 summarizes the design and doses of the Phase ha 3-way open label cross-over study;
FIG. 3 summarizes the entry criteria: inclusions of the Phase Ha 3-way open label cross-over study;
FIG. 4 summarizes the entry criteria: exclusions of the Phase Ha 3-way open label cross-over study;
FIG. 5 depicts a graph showing sample size: 30 for > 80% power to detect a delta of 35%
between control (bupropion) and Low Dose Lorexys and Moderate Dose Lorexys of the Phase ha 3-way open label cross-over study;
FIG. 6 summarizes the dispositions of the patients in the of the Phase ha 3-way open label cross-over study;
FIG. 7 summarizes the % responders for Moderate Dose Lorexys vs Bupropion of the Phase Ha 3-way open label cross-over study;
FIG. 8 summarizes the % of patients reaching remission for Low Dose Lorexys vs Bupropion of the Phase Ha 3-way open label cross-over study;
FIG. 9 summarizes Low Dose Lorexys intermediate efficacy as to patients' global impression of change, that is, % improved, for all those patients with an end of study evaluation of the Phase Ha 3-way open label cross-over study;
FIG. 10 summarizes the adverse events of the Phase ha 3-way open label cross-over study; and FIG. 11 summarizes the conclusions of the Phase Ha 3-way open label cross-over study.
Detailed Description of the Invention The present inventors have now discovered a therapeutic strategy that addresses hypoactive sexual desire disorder (HSDD) in a woman and, in particular, a pre-menopausal woman.
The present invention relates, at least in part, to the discovery that a combination of a 5-HT2A
antagonist (which is optionally a 5-HTIA receptor agonist), a norepinephrine-dopamine reuptake inhibitor, (and optionally an endocrine active agent) provides unexpected superior and synergistic results in addressing hypoactive sexual desire disorder (HSDD) in a subject.
1. Definitions Before further description of the present invention, and in order that the invention may be more readily understood, certain terms are first defined and collected here for convenience.
The term "administration" or "administering" includes routes of introducing the compound of the invention(s) to a subject to perform their intended function. Examples of routes of administration that may be used include injection (subcutaneous, intravenous, parenterally, intraperitoneally, intrathecal), oral, buccal, sublingual, inhalation, rectal and transdermal.
The pharmaceutical preparations may be given by forms suitable for each administration route. For example, these preparations are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred. The injection can be bolus or can be continuous infusion. Depending on the route of administration, the compound of the invention can be coated with or disposed in a selected material to protect it from natural conditions which may detrimentally effect its ability to perform its intended function. The compound of the invention can be administered alone, or in conjunction with either another agent as described above or with a pharmaceutically-acceptable carrier, or both. The compound of the invention can be administered prior to the administration of the other agent, simultaneously with the agent, or after the administration of the agent.
Furthermore, the compound of the invention can also be administered in a pro-drug form which is converted into its active metabolite, or more active metabolite in vivo.
The language "biological activities" of a compound of the invention includes all activities elicited by compound of the inventions in a responsive cell. It includes genomic and non-genomic activities elicited by these compounds.
"Biological composition" or "biological sample" refers to a composition containing or derived from cells or biopolymers. Cell-containing compositions include, for example, mammalian blood, red cell concentrates, platelet concentrates, leukocyte concentrates, blood cell proteins, blood plasma, platelet-rich plasma, a plasma concentrate, a precipitate from any fractionation of the plasma, a supernatant from any fractionation of the plasma, blood plasma protein fractions, purified or partially purified blood proteins or other components, serum, semen, mammalian colostrum, milk, saliva, placental extracts, a cryoprecipitate, a cryosupernatant, a cell lysate, mammalian cell culture or culture medium, products of fermentation, ascites fluid, proteins induced in blood cells, and products produced in cell culture by normal or transformed cells (e.g., via recombinant DNA or monoclonal antibody technology). Biological compositions can be cell-free. In a preferred embodiment, a suitable biological composition or biological sample is a red blood cell suspension. In some embodiments, the blood cell suspension includes mammalian blood cells. Preferably, the blood cells are obtained from a human, a non-human primate, a dog, a cat, a horse, a cow, a goat, a sheep or a pig. In preferred embodiments, the blood cell suspension includes red blood cells and/or platelets and/or leukocytes and/or bone marrow cells.
The term "effective amount" includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result, e.g., sufficient to treat a hypoactive sexual desire disorder in a subject. An effective amount of compound of the invention may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound of the invention to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the compound of the invention are outweighed by the therapeutically beneficial effects.
A therapeutically effective amount of compound of the invention (i.e., an effective dosage) may range from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.
The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present.
Moreover, treatment of a subject with a therapeutically effective amount of a compound of the invention can include a single treatment or, preferably, can include a series of treatments. In one example, a subject is treated with a compound of the invention in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of a compound of the invention used for treatment may increase or decrease over the course of a particular treatment. Administration regimens herein where designated are in accordance with the following abbreviations: SID or QD=Once a day; BID=Twice a day, TID=Three times a day; QID=Four times a day;
q.h.s=every night.
The term "homeostasis" is art-recognized to mean maintenance of static, or constant, conditions in an internal environment.
The language "improved biological properties" refers to any activity inherent in a compound of the invention that enhances its effectiveness in vivo. In a preferred embodiment, this term refers to any qualitative or quantitative improved therapeutic property of a compound of the invention, such as reduced toxicity.
The term "modulate" refers to an increase or decrease, e.g., the alteration in hypoactive sexual desire disorder and/or symptoms thereof in a subject such that a desired end result is achieved, e.g., a therapeutic result.
The term "obtaining" as in "obtaining a compound useful in treating hypoactive sexual desire disorder" is intended to include purchasing, synthesizing or otherwise acquiring the compound.
The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
The language "a prophylactically effective amount" of a compound refers to an amount of a compound of the invention any formula herein or otherwise described herein which is effective, upon single or multiple dose administration to the patient, in preventing or treating a sexual disorder.
The language "reduced toxicity" is intended to include a reduction in any undesired side effect elicited by a compound of the invention when administered in vivo.
The term "subject" includes organisms which are capable of suffering from a sexual disorder or who could otherwise benefit from the administration of a compound or composition of the invention, such as human (male or female) and non-human animals (male or female). Preferred humans include human patients suffering from or prone to suffering from hypoactive sexual desire disorder or associated state, as described herein. The term "non-human animals" of the invention includes all vertebrates, e.g., mammals, e.g., rodents, e.g., mice, and non-mammals, such as non-human primates, e.g., sheep, dog, cow, chickens, amphibians, reptiles, etc.
The term "susceptible to a hypoactive sexual desire disorder" is meant to include subjects at risk of developing hypoactive sexual desire disorder, e.g., subjects previously diagnosed as having or having a family or medical history of hypoactive sexual desire disorder, and the like.
The phrases "systemic administration, "administered systemically", "peripheral administration"
and "administered peripherally" as used herein mean the administration of a compound of the invention(s), drug or other material, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
The language "therapeutically effective amount" of a compound of the invention of the invention refers to an amount of an agent which is effective, upon single or multiple dose administration to the patient, in modulating hypoactive sexual desire disorder and/or symptoms of hypoactive sexual desire disorder, or in improving the patient (either objectively or subjectively according to the patient or health care provider) beyond that expected in the absence of such treatment.
2. Compounds of the Invention In one aspect, the invention provides compounds capable of modulating hypoactive sexual desire disorder in a subject. Such compounds include a 5-HT2A antagonist, a 5-HTIA
receptor agonist, a norepinephrine-dopamine reuptake inhibitor, and an endocrine active agent.
Compositions of the invention further include a pharmaceutically acceptable carrier.
The compounds delineated herein include a 5-HT2A antagonist, that is a compound that demonstrates antagonistic activity against the 5-HT2A receptor; a norepinephrine-dopamine reuptake inhibitor; that is a compound that exhibits inhibition activity in norepinephrine-dopamine reuptake; a 5-HTIA receptor agonist, that is a compound that demonstrates agonist activity against the 5-HTIA receptor; and an endocrine active agent, that is an agent that is active in modulating the endocrine system.
In one embodiment, the invention provides a compound (e.g., a compound herein) capable of modulating hypoactive sexual desire disorder; and pharmaceutically acceptable esters, salts, hydrates, solvates, isomers and prodrugs thereof Naturally occurring or synthetic isomers can be separated in several ways known in the art.
Methods for separating a racemic mixture of two enantiomers include chromatography using a chiral stationary phase (see, e.g., "Chiral Liquid Chromatography," W. J.
Lough, Ed. Chapman and Hall, New York (1989)). Enantiomers can also be separated by classical resolution techniques. For example, formation of diastereomeric salts and fractional crystallization can be used to separate enantiomers. For the separation of enantiomers of carboxylic acids, the diastereomeric salts can be formed by addition of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, and the like. Alternatively, diastereomeric esters can be formed with enantiomerically pure chiral alcohols such as menthol, followed by separation of the diastereomeric esters and hydrolysis to yield the free, enantiomerically enriched carboxylic acid.
For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.
3. Uses Of The Compounds of the Invention In one embodiment, the invention provides methods of treating hypoactive sexual desire disorder (HSDD) in a subject comprising administering to the subject a composition delineated herein. In certain embodiments, the subject is a mammal, e.g., a primate, e.g., a human.
In aspect, the disease, disorder or symptom thereof in which the compounds, compositions, and methods of treatment relate to is one described in the Diagnostic and Statistical Manual of Mental Disorders 4th edition--Text Revision, (DSM-I-TRV), American Psychiatric Association.
In certain embodiments, the methods of the invention include administering to a subject a therapeutically effective amount of a compound of the invention in combination with another pharmaceutically active compound. Examples of pharmaceutically active compounds include compounds known to treat hypoactive sexual desire disorder (HSDD) in a subject. Other pharmaceutically active compounds that may be used can be found in Harrison's Principles of Internal Medicine, Thirteenth Edition, Eds. T. R. Harrison et al. McGraw-Hill N.Y., NY; and the Physicians Desk Reference 50th Edition 1997, Oradell N.J., Medical Economics Co., the complete contents of which are expressly incorporated herein by reference. The compound of the invention and the pharmaceutically active compound may be administered to the subject in the same pharmaceutical composition or in different pharmaceutical compositions (at the same time or at different times).
Determination of a therapeutically effective hypoactive sexual desire disorder (HSDD) effective amount, a prophylactically effective hypoactive sexual desire disorder amount of the compound of the invention, can be readily made by the physician or veterinarian (the "attending clinician"), as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances. The dosages may be varied depending upon the requirements of the patient in the judgment of the attending clinician; the severity of the condition being treated and the particular compound being employed. In determining the therapeutically effective hypoactive sexual desire disorder amount or dose, and the prophylactically effective hypoactive sexual desire disorder amount or dose, a number of factors are considered by the attending clinician, including, but not limited to: the specific hypoactive sexual desire disorder involved;
pharmacodynamic characteristics of the particular agent and its mode and route of administration; the desired time course of treatment; the species of mammal;
its size, age, and general health; the specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the kind of concurrent treatment (i.e., the interaction of the compound of the invention with other co-administered therapeutics); and other relevant circumstances.
The dosage administration can be in a single dosage form or multiple dosage forms. The dosages can be administered concurrently, simultaneously, or sequentially. The dosages can be a single dosage immediately prior to sexual activity, or can be one or more doses daily without regard to timing prior to sexual activity. Treatment can be initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage may be increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. A
therapeutically effective amount and a prophylactically effective amount of a compound of the invention of the invention is expected to vary from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 100 mg/kg/day.
The identification of those patients who are in need of prophylactic treatment for hypoactive sexual desire disorder is well within the ability and knowledge of one skilled in the art. Certain of the methods for identification of patients which are at risk of developing hypoactive sexual desire disorder which can be treated by the subject method are appreciated in the medical arts, such as family history, and the presence of risk factors associated with the development of that disease state in the subject patient (e.g., use of antidepressant drugs, hormonal contraceptives, antihormonal and/or cytotoxic chemotherapies, sedatives, antipsychotic drugs, antiepileptic drugs, mood stabilizer drugs, opioid drugs, alcohol, or narcotic drugs). A
clinician skilled in the art can readily identify such candidate patients, by the use of, for example, clinical tests, physical examination and medical/family history.
As used herein, "obtaining a biological sample from a subject," includes obtaining a sample for use in the methods described herein. A biological sample is described above.
In another aspect, a compound of the invention is packaged in a therapeutically effective amount with a pharmaceutically acceptable carrier or diluent. The composition may be formulated for treating a subject suffering from or susceptible to a hypoactive sexual desire disorder, and packaged with instructions to treat a subject suffering from or susceptible to a hypoactive sexual desire disorder.
The subject may be at risk of a hypoactive sexual desire disorder, may be exhibiting symptoms of a hypoactive sexual desire disorder, may be susceptible to a hypoactive sexual desire disorder and/or may have been diagnosed with a sexual desire disorder.
If the modulation of the status indicates that the subject may have a favorable clinical response to the treatment, the subject may be treated with the compound. For example, the subject can be administered therapeutically effective dose or doses of the compound.
Kits of the invention include kits for treating a hypoactive sexual desire disorder in a subject.
The kit may include a compound of the invention, for example, a compound described herein, pharmaceutically acceptable esters, salts, and prodrugs thereof, and instructions for use. The instructions for use may include information on dosage, method of delivery, storage of the kit, etc. In aspects, the kits (and methods of using them) comprise instructions indicating that the compositions and/or treatment methods are contraindicated for (or not to be administered to) subjects that: (1) require and/or are taking CYP3A4, CYP 2B6-, or CYP 2D6-metabolized drugs;
(ii) take any sex hormone other than an approved hormonal contraceptive; (iii) drink more than one alcoholic drink per day (e.g., 12-oz beer, 4-oz wine, etc).
Alternatively, the effects of compound of the invention can be characterized in vivo using animals models.
4. Pharmaceutical Compositions The invention also provides a pharmaceutical composition, comprising an effective amount of a compound described herein and a pharmaceutically acceptable carrier. In a further embodiment, the effective amount is effective to treat a hypoactive sexual desire disorder, as described previously.
In an embodiment, the compound of the invention is administered to the subject using a pharmaceutically-acceptable formulation, e.g., a pharmaceutically-acceptable formulation that provides sustained delivery of the compound of the invention to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.
In certain embodiments, these pharmaceutical compositions are suitable for topical or oral, buccal or sublingual administration to a subject. In other embodiments, as described in detail below, the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) topical application, for example, as a cream, ointment or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; or (5) aerosol, for example, as an aqueous aerosol, liposomal preparation or solid particles containing the compound or composition herein.
The phrase "pharmaceutically acceptable" refers to those compound of the inventions of the present invention, compositions containing such compounds, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The phrase "pharmaceutically-acceptable carrier" includes pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body. Each carrier is "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch;
(3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc;
(8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
Compositions containing a compound of the invention(s) include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, more preferably from about 10 percent to about 30 percent.
Methods of preparing these compositions include the step of bringing into association a compound of the invention(s) with the carrier and, optionally, one or more accessory ingredients.
In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
Compositions of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, caplets, gel caps, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the invention(s) as an active ingredient. A compound may also be administered as a bolus, electuary or paste.
In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
Liquid dosage forms for oral administration of the compound of the invention(s) include pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
In addition to inert diluents, the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
Suspensions, in addition to the active compound of the invention(s) may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof Pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compound of the invention(s) with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.
Compositions of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
Dosage forms for the topical or transdermal administration of a compound of the invention(s) include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound of the invention(s) may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
The ointments, pastes, creams and gels may contain, in addition to compound of the invention(s) of the present invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to a compound of the invention(s), excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
The compound of the invention(s) can be alternatively administered by aerosol.
This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound. A nonaqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers are preferred because they minimize exposing the agent to shear, which can result in degradation of the compound.
Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of the agent together with conventional pharmaceutically-acceptable carriers and stabilizers, The carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aerosols generally are prepared from isotonic solutions.
Transdermal patches have the added advantage of providing controlled delivery of a compound of the invention(s) to the body. Such dosage forms can be made by dissolving or dispersing the agent in the proper medium. Absorption enhancers can also be used to increase the flux of the active ingredient across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active ingredient in a polymer matrix or gel.
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of the invention.
Pharmaceutical compositions of the invention suitable for parenteral administration comprise one or more compound of the invention(s) in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
Examples of suitable aqueous and nonaqueous carriers, which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions.
In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsule matrices of compound of the invention(s) in biodegradable polymers such as polylactide-polyglycolide.
Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemuisions which are compatible with body tissue.
When the compound of the invention(s) are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically-acceptable carrier.
Regardless of the route of administration selected, the compound of the invention(s), which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
Actual dosage levels and time course of administration of the active ingredients in the pharmaceutical compositions of the invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. An exemplary dose range is from 0.1 to 10 mg per day.
A preferred dose of the compound of the invention for the present invention is the maximum that a patient can tolerate and not develop serious side effects. Preferably, the compound of the invention of the present invention is administered at a concentration of about 0.001 mg to about 100 mg per kilogram of body weight, about 0.001--about 10 mg/kg or about 0.001 mg--about 100 mg/kg of body weight. Ranges intermediate to the above-recited values are also intended to be part of the invention.
5. Example The invention is further illustrated by the following example which is intended to illustrate but not limit the scope of the invention.
Low Dose Lorexys and High Dose Lorexys HSDD Clinical Study in Premenopausal Women We sought to estimate the prevalence of low sexual desire and hypoactive sexual desire disorder (HSDD) in US women, focusing on their menopausal status.
Methods:
An open cross-sectional study was performed. From a probability sample of households, 2207 US women aged 30 to 70 years and in stable relationships (>or=3 months) were interviewed by telephone. The analysis focused on 755 premenopausal women and 552 naturally and 637 surgically menopausal women. Low sexual desire was defined using the Profile of Female Sexual Function desire domain, and HSDD was defined using the Profile of Female Sexual Function and the Personal Distress Scale.
Results:
Prevalence of low sexual desire ranged from 26.7% among premenopausal women to 52.4%
among naturally menopausal women. The prevalence of HSDD was highest among surgically menopausal women (12.5%). Compared with premenopausal women and adjusting for age, race/ethnicity, educational level, and smoking status, the prevalence ratios for HSDD were 2.3 (95% confidence interval, 1.2-4.5) for surgically menopausal women and 1.2 (0.5-2.8) for naturally menopausal women; the prevalence ratios for low sexual desire were 1.3 (0.9-1.9) and 1.5 (1.0-2.2) for surgically and naturally menopausal women, respectively.
Conclusions:
Prevalence of low sexual desire is elevated among surgically and naturally menopausal women vs premenopausal women. Distress about low desire (HSDD) appears to be more than twice as prevalent among surgically menopausal women vs premenopausal women, although the estimate is fairly imprecise.
Hyposexual desire disorder {HSDD) remains without approved pharmacotherapies, though one CNS agent, bupropion, is recommended. This study tested the efficacy and safety of Lorexys, a proprietary combination of bupropion and trazodone, in premenopausal women.
A clinical study was conducted with Lorexys to treat premenopausal women for HSDD. The study's primary objective was to evaluate Lorexys' safety, tolerability and pro-sexual efficacy as compared to bupropion, one of its constituent drugs. Other objectives included exploration of the onset and duration of action of Lorexys.
The study had an adaptive, three-way crossover, open-label design. It enrolled 30 premenopausal women who met the DSM-IV-TR criteria for HSDD, and it also assessed patients for the newly defined DSM-5 Sexual Interest and Arousal Disorder. Each subject received a daily dose of bupropion as an active control for four weeks followed by a week-long washout period, then daily administration of a low dose of Lorexys for four weeks followed by another washout period, and, finally, a moderate dose of Lorexys for four weeks followed by another washout period.
The dosing and treatment regimens for the study were as follows:
Active Control: Bupropion SR 300 mg was administered once daily in the morning for four weeks.
Low Dose Lorexys: Low dose Lorexys is combination therapy that consists of two drugs: buproprion and trazadone. burpropion SR 150 mg was administered once daily in the morning and trazadone ER 75 mg was administered once daily at bedtime, each for four weeks.
Moderate Dose Lorexys: Moderate dose Lorexys is also combination therapy that consist of two drugs: buproprion and trazadone. burpropion SR 150 mg was administered twice daily, once in the morning and once eight (8) hours later, and trazadone ER
150 mg was administered once daily at bedtime, each for four weeks.
Patients self-evaluated weekly with questionnaires and were assessed during eight clinic visits.
Outcome measures for efficacy included validated self-rated scales of Sexual Function and Sexual Distress and global change. Outcome measures for safety included comprehensive evaluations of symptoms and vital signs, plus standard laboratory studies and electrocardiograms. The study was conducted at two clinical sites in the U.S.
Materials and Methods:
This was an open-label crossover study in non-depressed, otherwise healthy patients with DSM-IV-TR HSDD, aged 25-50 years, with four weeks per treatment. With n=30 and 33%
more Lorexys responders vs. Bupropion SR, the power at a =0.05 was 80%. Four weeks of Bupropion SR at 300 mg/day and a washout was followed by four weeks of Lorexys low-dose (LOR-low), i.e, Bupropion SR plus Trazodone ER at doses lower than the labeled doses, followed by another washout and four weeks of Lorexys moderate-dose (LORmod; 2x LOR-low).The primary efficacy endpoint was Female Sexual Function Index Desire domain (FSFI-d); the key secondary was Female Sexual Distress Scale-Revised (FSDS-R). Analyses included %
responders and %
remitters from the first baseline, using standard definitions (see Table 1) for FSFI-d and FSDS-R
item 13 (FSDS-R-i13), plus Patient's Global Impression of Change (PGIC). See FIGS. 1-11.
Results Five patients (17%) discontinued for administrative reasons; one (4%) discontinued for adverse events, on LOR-mod. Table 1 below shows responder and remitter rates with LOR-mod; rates with LOR-low were intermediate and non-significant vs. bupropion.
Conclusion Lorexys was highly superior to bupropion in non-depressed, otherwise healthy, premenopausal HSDD to Bupropion SR alone in the treatment of premenopausal women for HSDD. See Table 1 and FIGS. 1-11.
Table 1. Results Measure Definition LOR-mod Bupropion p-value on Fisher's Exact test, 2-tailed Responders FSFI-d 2-point increase 76% 38% <0.01 FSDS-R-i13 1-point decrease 88% 45% <0.01 PGIC >=Moderately 58% 24% <0.05 Improved Remitters FSFI-d >=5 58% 24% <0.05 FSDS-R-i13 <=2 75% 32% <0.01 The disclosures of each and every patent, patent application and publication cited herein are hereby incorporated herein by reference in their entireties.
The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
Although the invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of the invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The claims are intended to be construed to include all such embodiments and equivalent variations.
Claims
Having describe my invention, I claim:
(1) A method of treating a woman for HSDD with a combination treatment comprising at least two different drugs, wherein the woman is need of HSDD treatment, said method comprising:
(a) administering to the woman daily a first drug having a dosage strength of 150 mg, wherein the first drug is bupropion;
(b) administering to the woman daily a second drug having a dosage strength of 75 mg, wherein the second drug is trazodone; and (c) wherein said administration of said first drug and said second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.
(2) A method of claim 1, wherein said administrations of said first drug and said second drug is on the same day during the prescribed treatment regimen.
(3) A method of claim 1, wherein said prescribed treatment regimen is for at least about 30 days.
(4) A method of claim 1, wherein said prescribed treatment regimen is for about one or more months.
(5) A method of claim 1, wherein said prescribed treatment regimen is for about one year.
(6) A method of claim 1, wherein said prescribed treatment regimen is for about one or more years.
(7) A method of claim 1, wherein the bupropion is in an oral extended or sustained released dosage form.
(8) A method of claim 1, wherein the trazodone is in an oral extended or sustained release dosage form.
(9) A method of claim 1, wherein the bupropion is in an oral extended or sustained released dosage form and the trazodone is in an oral extended release dosage form.
(10) A method of claim 1, wherein the woman is a premenopausal woman.
(11) A method of claim 1, wherein said administration of the first drug comprises administering the first drug to the woman in the morning.
(12) A method of claim 1, wherein said administration of the second drug comprises administering the second drug to the woman in the evening.
(13) A method of claim 1, wherein said administration of the second drug comprises administering the second drug to the woman at bedtime.
(14) A method of treating a woman for HSDD with a combination treatment comprising at least two different drugs, wherein the woman is need of HSDD treatment, said method comprising:
(a) administering to the woman daily a first drug in a dosage strength of 300 mg, wherein the first drug is bupropion; and (b) administering to the woman daily a second drug in a dosage strength of 150 mg, wherein the second drug is trazodone;
(c) wherein said administration of said first drug and said second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.
(15) A method of claim 14, wherein said administrations of said first drug and said second drug is on the same day during the prescribed treatment regimen.
(16) A method of claim 14, wherein said prescribed treatment regimen is for at least about 30 days.
(17) A method of claim 14, wherein said prescribed treatment regimen is for about one or more months.
(18) A method of claim 14, wherein said prescribed treatment regimen is for about one year.
(19) A method of claim 14, wherein said prescribed treatment regimen is for about one or more years (20) A method of claim 14, wherein the bupropion is in an oral extended released dosage form.
(21) A method of claim 14, wherein the trazodone is in an oral extended or sustained release dosage form.
(22) A method of claim 14, wherein the bupropion is in an oral extended or sustained released dosage form and the trazodone is in an oral extended release dosage form.
(23) A method of claim 14, wherein the woman is a premenopausal woman.
(24) A method of claim 14, wherein said administration of the first drug comprises administering the first drug to the woman in a first dose of 150 mg the morning, and a second dose of 150 mg in the evening.
(25) A method of claim 14, wherein said administration of the second drug comprises administering the second drug to the woman in the evening.
(26) A method of claim 1, wherein said administration of the second drug comprises administering the second drug to the woman at bedtime.
(27) A method of treating a woman for HSDD with a combination treatment comprising at least two different drugs, wherein the woman is need of HSDD treatment, said method comprising:
administering to the woman daily Low Dose Lorexys, wherein said administration of said first drug and said second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.
(28) A method of treating a woman for HSDD with a combination treatment comprising at least two different drugs, wherein the woman is need of HSDD treatment, said method comprising:
administering to the woman daily Moderate Dose Lorexys, wherein said administration of said first drug and said second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.
(29) A method of treating a woman for HSDD with a combination treatment comprising at least two different drugs, wherein the woman is need of HSDD treatment, said method comprising:
(a) administering to the woman daily a first drug having a dosage strength in the range of between about 150 mg and 300 mg, wherein the first drug is bupropion;
(b) administering to the woman daily a second drug having a dosage strength in the range of between about 75 mg and 150 mg, wherein the second drug is trazodone;
and (c) wherein said administration of said first drug and said second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.
(30) A method of claim 29, wherein the trazodone and the bupropion are in an oral extended or sustained released dosage form and the trazodone is in an oral extended release dosage form.
(31) A method of claim 29, wherein the trazodone and the bupropion are formulated into a single oral unitary dosage form.
(32) A method of claim 29, wherein the single oral unitary dosage form is a tablet.
(33) A method of claim 29, wherein the single oral unitary dosage form is a caplet.
(34) A method of claim 29, wherein the single oral unitary dosage form is a capsule.
(35) A method of anyone of claims 1-34, wherein the bupropion and the trazodone include their respective pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug forms.
(36) The use of trazadone and bupropion in the manufacture of a medicament for the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone is in an amount of about 75 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion is in an amount of about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, wherein the medicament is to be administered orally, and wherein the treatment is to be daily and continued in accordance with a prescribed treatment regimen.
(37) The use of claim 36, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(38) The use of claim 36, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(39) The use of claim 36, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(40) The use of claims 36, 37, 38 or 39, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(41) The use of claim 40, wherein the single oral unitary dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(42) The use of claims 36, 37, 38 or 39, wherein the trazadone and bupropion are each in a separate oral dosage form.
(43) The use of claim 47, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(44) Trazadone in an amount of about 75 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion in an amount of between about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, for combination use in the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone and bupropion are to be administered orally, and wherein the treatment is to be daily and continued in accordance with a prescribed treatment regimen.
(45) The combination use of claim 44, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(46) The combination use of claim 44, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(47) The combination use of claim 44, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(48) The combination use of claims 44, 45,46 or 47, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(49) The combination use of claim 48, wherein the single oral unitary dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(50) The combination use of claims 44, 45, 46 or 47, wherein the trazadone and bupropion are each in a separate oral dosage form.
(51) The combination use of claim 50, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(52) The use of trazadone and bupropion in the manufacture of a medicament for the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone is in an amount of about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion is in an amount of about 300 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, wherein the medicament is to be administered orally, and wherein the treatment is to be daily and continued in accordance with a prescribed treatment regimen.
(53) The use of claim 52, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(54) The use of claim 52, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(55) The use of claim 52, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(56) The use of claims 52, 53, 54 or 55, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(57) The use of claim 56, wherein the single oral unitary dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(58) The use of claims 52, 53, 54 or 55, wherein the trazadone and bupropion are each in a separate oral dosage form.
(59) The use of claim 58, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(60) Trazadone in an amount of about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion in an amount of between about 300 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, for combination use in the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone and bupropion are to be administered orally, and wherein the treatment is to be daily and continued in accordance with a prescribed treatment regimen.
(61) The combination use of claim 60, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(62) The combination use of claim 60, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(63) The combination use of claim 60, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(64) The combination use of claims 60, 61, 62, or 63, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(65) The combination use of claim 64, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(66) The combination use of claims 60, 61, 62, or 63, wherein the trazadone and bupropion are each in separate oral dosage forms.
(67) The combination use of claim 66, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(68) The use of trazadone and bupropion in the manufacture of a medicament for the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone is in an amount of between about 75 mg and about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion is in an amount of between about 150 mg and about 300 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, wherein the medicament is to be administered orally, and wherein the treatment is to be daily and continued in accordance with a prescribed treatment regimen.
(69) The use of claim 68, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(70) The use of claim 68, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(71) The use of claim 68, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(72) The use of claims 68, 69, 70, or 71, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(73) The use of claim 72, wherein the single oral unitary dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(74) The use of claims 68, 69, 70, or 71, wherein the trazadone and bupropion are each in a separate oral dosage form.
(75) The use of claim 74, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(76) Trazadone in an amount of between about 75 mg and about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion in an amount of between about 150 mg and about 300 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, for combination use in the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone and bupropion are to be administered orally, and wherein the treatment is to daily and be continued in accordance with a prescribed treatment regimen.
(77) The cornbination use of claim 76, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(78) The combination use of claim 76, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(79) The combination use of claim 76, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(80) The combination use of claims 76, 77, 78 or 79, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(81) The combination use of claim 80, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(82) The combination use of claims 76, 77, 78 or 79, wherein the trazadone and bupropion are each in separate oral dosage forms.
(83) The combination use of claim 82, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(1) A method of treating a woman for HSDD with a combination treatment comprising at least two different drugs, wherein the woman is need of HSDD treatment, said method comprising:
(a) administering to the woman daily a first drug having a dosage strength of 150 mg, wherein the first drug is bupropion;
(b) administering to the woman daily a second drug having a dosage strength of 75 mg, wherein the second drug is trazodone; and (c) wherein said administration of said first drug and said second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.
(2) A method of claim 1, wherein said administrations of said first drug and said second drug is on the same day during the prescribed treatment regimen.
(3) A method of claim 1, wherein said prescribed treatment regimen is for at least about 30 days.
(4) A method of claim 1, wherein said prescribed treatment regimen is for about one or more months.
(5) A method of claim 1, wherein said prescribed treatment regimen is for about one year.
(6) A method of claim 1, wherein said prescribed treatment regimen is for about one or more years.
(7) A method of claim 1, wherein the bupropion is in an oral extended or sustained released dosage form.
(8) A method of claim 1, wherein the trazodone is in an oral extended or sustained release dosage form.
(9) A method of claim 1, wherein the bupropion is in an oral extended or sustained released dosage form and the trazodone is in an oral extended release dosage form.
(10) A method of claim 1, wherein the woman is a premenopausal woman.
(11) A method of claim 1, wherein said administration of the first drug comprises administering the first drug to the woman in the morning.
(12) A method of claim 1, wherein said administration of the second drug comprises administering the second drug to the woman in the evening.
(13) A method of claim 1, wherein said administration of the second drug comprises administering the second drug to the woman at bedtime.
(14) A method of treating a woman for HSDD with a combination treatment comprising at least two different drugs, wherein the woman is need of HSDD treatment, said method comprising:
(a) administering to the woman daily a first drug in a dosage strength of 300 mg, wherein the first drug is bupropion; and (b) administering to the woman daily a second drug in a dosage strength of 150 mg, wherein the second drug is trazodone;
(c) wherein said administration of said first drug and said second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.
(15) A method of claim 14, wherein said administrations of said first drug and said second drug is on the same day during the prescribed treatment regimen.
(16) A method of claim 14, wherein said prescribed treatment regimen is for at least about 30 days.
(17) A method of claim 14, wherein said prescribed treatment regimen is for about one or more months.
(18) A method of claim 14, wherein said prescribed treatment regimen is for about one year.
(19) A method of claim 14, wherein said prescribed treatment regimen is for about one or more years (20) A method of claim 14, wherein the bupropion is in an oral extended released dosage form.
(21) A method of claim 14, wherein the trazodone is in an oral extended or sustained release dosage form.
(22) A method of claim 14, wherein the bupropion is in an oral extended or sustained released dosage form and the trazodone is in an oral extended release dosage form.
(23) A method of claim 14, wherein the woman is a premenopausal woman.
(24) A method of claim 14, wherein said administration of the first drug comprises administering the first drug to the woman in a first dose of 150 mg the morning, and a second dose of 150 mg in the evening.
(25) A method of claim 14, wherein said administration of the second drug comprises administering the second drug to the woman in the evening.
(26) A method of claim 1, wherein said administration of the second drug comprises administering the second drug to the woman at bedtime.
(27) A method of treating a woman for HSDD with a combination treatment comprising at least two different drugs, wherein the woman is need of HSDD treatment, said method comprising:
administering to the woman daily Low Dose Lorexys, wherein said administration of said first drug and said second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.
(28) A method of treating a woman for HSDD with a combination treatment comprising at least two different drugs, wherein the woman is need of HSDD treatment, said method comprising:
administering to the woman daily Moderate Dose Lorexys, wherein said administration of said first drug and said second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.
(29) A method of treating a woman for HSDD with a combination treatment comprising at least two different drugs, wherein the woman is need of HSDD treatment, said method comprising:
(a) administering to the woman daily a first drug having a dosage strength in the range of between about 150 mg and 300 mg, wherein the first drug is bupropion;
(b) administering to the woman daily a second drug having a dosage strength in the range of between about 75 mg and 150 mg, wherein the second drug is trazodone;
and (c) wherein said administration of said first drug and said second drug is in accordance with a prescribed treatment regimen for treating the woman for HSDD.
(30) A method of claim 29, wherein the trazodone and the bupropion are in an oral extended or sustained released dosage form and the trazodone is in an oral extended release dosage form.
(31) A method of claim 29, wherein the trazodone and the bupropion are formulated into a single oral unitary dosage form.
(32) A method of claim 29, wherein the single oral unitary dosage form is a tablet.
(33) A method of claim 29, wherein the single oral unitary dosage form is a caplet.
(34) A method of claim 29, wherein the single oral unitary dosage form is a capsule.
(35) A method of anyone of claims 1-34, wherein the bupropion and the trazodone include their respective pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug forms.
(36) The use of trazadone and bupropion in the manufacture of a medicament for the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone is in an amount of about 75 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion is in an amount of about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, wherein the medicament is to be administered orally, and wherein the treatment is to be daily and continued in accordance with a prescribed treatment regimen.
(37) The use of claim 36, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(38) The use of claim 36, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(39) The use of claim 36, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(40) The use of claims 36, 37, 38 or 39, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(41) The use of claim 40, wherein the single oral unitary dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(42) The use of claims 36, 37, 38 or 39, wherein the trazadone and bupropion are each in a separate oral dosage form.
(43) The use of claim 47, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(44) Trazadone in an amount of about 75 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion in an amount of between about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, for combination use in the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone and bupropion are to be administered orally, and wherein the treatment is to be daily and continued in accordance with a prescribed treatment regimen.
(45) The combination use of claim 44, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(46) The combination use of claim 44, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(47) The combination use of claim 44, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(48) The combination use of claims 44, 45,46 or 47, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(49) The combination use of claim 48, wherein the single oral unitary dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(50) The combination use of claims 44, 45, 46 or 47, wherein the trazadone and bupropion are each in a separate oral dosage form.
(51) The combination use of claim 50, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(52) The use of trazadone and bupropion in the manufacture of a medicament for the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone is in an amount of about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion is in an amount of about 300 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, wherein the medicament is to be administered orally, and wherein the treatment is to be daily and continued in accordance with a prescribed treatment regimen.
(53) The use of claim 52, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(54) The use of claim 52, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(55) The use of claim 52, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(56) The use of claims 52, 53, 54 or 55, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(57) The use of claim 56, wherein the single oral unitary dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(58) The use of claims 52, 53, 54 or 55, wherein the trazadone and bupropion are each in a separate oral dosage form.
(59) The use of claim 58, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(60) Trazadone in an amount of about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion in an amount of between about 300 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, for combination use in the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone and bupropion are to be administered orally, and wherein the treatment is to be daily and continued in accordance with a prescribed treatment regimen.
(61) The combination use of claim 60, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(62) The combination use of claim 60, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(63) The combination use of claim 60, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(64) The combination use of claims 60, 61, 62, or 63, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(65) The combination use of claim 64, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(66) The combination use of claims 60, 61, 62, or 63, wherein the trazadone and bupropion are each in separate oral dosage forms.
(67) The combination use of claim 66, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(68) The use of trazadone and bupropion in the manufacture of a medicament for the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone is in an amount of between about 75 mg and about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion is in an amount of between about 150 mg and about 300 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, wherein the medicament is to be administered orally, and wherein the treatment is to be daily and continued in accordance with a prescribed treatment regimen.
(69) The use of claim 68, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(70) The use of claim 68, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(71) The use of claim 68, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(72) The use of claims 68, 69, 70, or 71, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(73) The use of claim 72, wherein the single oral unitary dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(74) The use of claims 68, 69, 70, or 71, wherein the trazadone and bupropion are each in a separate oral dosage form.
(75) The use of claim 74, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(76) Trazadone in an amount of between about 75 mg and about 150 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or prodrug thereof, and bupropion in an amount of between about 150 mg and about 300 mg, and any pharmaceutically acceptable salt, ester, hydrate, solvate, isomer and prodrug thereof, for combination use in the treatment of hypoactive sexual desire disorder (HSDD), wherein the trazodone and bupropion are to be administered orally, and wherein the treatment is to daily and be continued in accordance with a prescribed treatment regimen.
(77) The cornbination use of claim 76, wherein the trazodone is in an oral extended or sustained release dosage form and the bupropion is in an oral extended or sustained release dosage form.
(78) The combination use of claim 76, wherein the trazodone and the bupropion are each in an oral immediate release dosage form.
(79) The combination use of claim 76, wherein the trazodone and the bupropion are in the same or different oral dosage forms, wherein the oral dosage forms are selected from a group of oral dosage forms consisting of an oral immediate release dosage form, an oral extended release dosage form and an oral sustained release dosage form.
(80) The combination use of claims 76, 77, 78 or 79, wherein the medicament is a single oral unitary dosage form comprised of both the trazodone and the bupropion.
(81) The combination use of claim 80, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
(82) The combination use of claims 76, 77, 78 or 79, wherein the trazadone and bupropion are each in separate oral dosage forms.
(83) The combination use of claim 82, wherein the separate oral dosage form is selected from a group consisting of a tablet, a caplet, a capsule, a gel cap, a pill, a cachet, a lozenge, a powder and granules.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662351904P | 2016-06-17 | 2016-06-17 | |
US62/351,904 | 2016-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2933921A1 true CA2933921A1 (en) | 2017-12-17 |
Family
ID=57758862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2933921A Abandoned CA2933921A1 (en) | 2016-06-17 | 2016-06-20 | Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment |
Country Status (9)
Country | Link |
---|---|
KR (1) | KR20170142797A (en) |
AR (2) | AR105047A1 (en) |
AU (1) | AU2016204151A1 (en) |
CA (1) | CA2933921A1 (en) |
CL (1) | CL2016001597A1 (en) |
MX (1) | MX2016008272A (en) |
PE (1) | PE20180023A1 (en) |
UY (1) | UY36742A (en) |
WO (1) | WO2017218018A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5897864A (en) * | 1996-05-23 | 1999-04-27 | Cohen; Alan J. | Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba |
HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
BRPI0510074A (en) * | 2004-04-22 | 2007-10-16 | Boehringer Ingelheim Int | pharmaceutical compositions for the treatment of sexual disorders ii |
CA2644662A1 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | New therapeutic combinations for the treatment of depression |
SG10201908587PA (en) * | 2012-08-06 | 2019-10-30 | S1 Pharmaceuticals Inc | Treatment regimens |
-
2016
- 2016-06-20 WO PCT/US2016/038386 patent/WO2017218018A1/en active Application Filing
- 2016-06-20 PE PE2016000848A patent/PE20180023A1/en unknown
- 2016-06-20 AU AU2016204151A patent/AU2016204151A1/en not_active Abandoned
- 2016-06-20 CL CL2016001597A patent/CL2016001597A1/en unknown
- 2016-06-20 UY UY0001036742A patent/UY36742A/en not_active Application Discontinuation
- 2016-06-20 MX MX2016008272A patent/MX2016008272A/en unknown
- 2016-06-20 CA CA2933921A patent/CA2933921A1/en not_active Abandoned
- 2016-06-20 KR KR1020160076915A patent/KR20170142797A/en not_active Application Discontinuation
- 2016-06-21 AR ARP160101828A patent/AR105047A1/en unknown
- 2016-06-21 AR ARP160101856A patent/AR105087A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016204151A1 (en) | 2018-01-18 |
AR105047A1 (en) | 2017-08-30 |
WO2017218018A1 (en) | 2017-12-21 |
AR105087A1 (en) | 2017-09-06 |
UY36742A (en) | 2016-12-30 |
MX2016008272A (en) | 2017-12-18 |
PE20180023A1 (en) | 2018-01-09 |
KR20170142797A (en) | 2017-12-28 |
CL2016001597A1 (en) | 2017-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002038142A2 (en) | Serotonergic compositions and methods for treatment of mild cognitive impairment | |
US20230270753A1 (en) | Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment | |
US20240269110A1 (en) | Compositions comprising aticaprant | |
AU2018264030A1 (en) | Treatment regimens | |
AU2018205121A1 (en) | Treatment regimens | |
Kohen et al. | Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports | |
TW200300672A (en) | Treatment of cognitive failure | |
CA2933921A1 (en) | Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment | |
KR20210151162A (en) | Carbamoyl Cyclohexane Derivatives for Treating Autism Spectrum Disorder | |
JP2019094304A (en) | Autophagy derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20200831 |